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Abstract: 60 
Objective: The objective of this document is to generate a practice guideline for the 61 
management and treatment of symptoms of the menopause. 62 
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Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for 80 
vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the 81 
majority of symptomatic postmenopausal women who are under age 60 or under 10 years since 82 
the onset of menopause. Health care professionals should individualize therapy based on clinical 83 
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factors and patient preference. They should screen women prior to initiating MHT for 84 
cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on 85 
risk/benefit considerations. Current evidence does not justify the use of MHT to prevent 86 
coronary heart disease, breast cancer, or dementia.  Other options are available for those with 87 
vasomotor symptoms who prefer not to use MHT or who have contraindications, as these 88 
patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective 89 
therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants 90 
are available for those not choosing hormonal therapy. All postmenopausal women should 91 
embrace appropriate lifestyle measures. 92 
 93 
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oxidase; MetS = metabolic syndrome; MHT = menopausal hormone therapy including ET and/or 105 
EPT; MI = myocardial infarction; MPA = medroxyprogesterone acetate; NCI = National Cancer 106 
Institute; OTC = over the counter; PE = pulmonary embolism; POI = primary ovarian 107 
insufficiency; QOL = quality of life; RCT = randomized controlled trial; REM = rapid eye 108 
movement; RR = relative risk; SERM = selective estrogen receptor modulator; SSRI = selective 109 
serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor; SWAN = 110 
Study of Women Across the Nation; TG = triglycerides; TIA = transient ischemic attack; VMS = 111 
vasomotor symptoms; VTE = venous thromboembolism; VVA = vulvovaginal atrophy; WHI = 112 
Women’s Health Initiative 113 
 114 
 115 
 116 
 117 
 118 
 119 
SUMMARY OF RECOMMENDATIONS   120 
1.0 Diagnosis and Symptoms of Menopause 121 
1.1 We suggest diagnosing menopause based on the clinical criteria of the menstrual cycle. 122 
(2|⊕⊕OO) 123 
1.2 If establishing a diagnosis of menopause is necessary for patient management in women 124 
having undergone a hysterectomy without bilateral oophorectomy or presenting with a menstrual 125 
 Confidential.  JCEM Submission 4 REVISED                     May 7, 2015; July 17 2015; August 11, 2015;  
                                                                      August 19, 2015                                                                                                                        
 
7 
 
history that is inadequate to ascertain menopausal status, we suggest making a presumptive 126 
diagnosis of menopause based on the presence of vasomotor symptoms  (VMS) and, when 127 
indicated, laboratory testing that includes replicate measures of follicle stimulating hormone 128 
(FSH) and serum estradiol. (2|⊕⊕OO) 129 
2.0 Health Considerations for All Menopausal Women  130 
2.1 When women present during the menopausal transition, we suggest using this opportunity to 131 
address bone health, smoking cessation, alcohol use, cardiovascular risk assessment and 132 
management, and cancer screening and prevention. (Ungraded best practice statement) 133 
3.0 Hormone Therapy for Menopausal Symptom Relief  134 
3.1 Estrogen and Progestogen Therapy 135 
3.1a For menopausal women < 60 years of age or < 10 years past menopause with bothersome 136 
VMS (with or without additional climacteric symptoms) who do not have contraindications or 137 
excess cardiovascular or breast cancer risks and are willing to take menopausal hormone therapy 138 
(MHT), we suggest initiating estrogen therapy (ET) for those without a uterus, and estrogen plus 139 
progestogen therapy (EPT) for those with a uterus. (2|⊕⊕OO) 140 
Cardiovascular Risk 141 
3.1b For women < age 60 or < 10 years past menopause onset considering MHT for menopausal 142 
symptom relief, we suggest evaluating the baseline risk of cardiovascular disease (CVD) and 143 
taking this risk into consideration when advising for or against MHT and when selecting type, 144 
dose, and route of administration. (2|⊕⊕OO)  145 
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3.1c For women at high risk of CVD, we suggest initiating non-hormonal therapies to alleviate 146 
bothersome VMS (with or without climacteric symptoms) over MHT. (2|⊕⊕OO) 147 
3.1d For women with moderate risk of CVD, we suggest transdermal estradiol as first-line 148 
treatment, alone for women without a uterus or combined with micronized progesterone (or 149 
another progestogen that does not adversely modify metabolic parameters) for women with a 150 
uterus, as these preparations have less untoward effect on blood pressure, triglycerides, and 151 
carbohydrate metabolism. (2|⊕⊕OO) 152 
Venous Thromboembolic Events 153 
3.1e For women at increased risk of venous thromboembolism (VTE) who request MHT, we 154 
recommend a non-oral route of ET at the lowest effective dose, if not contraindicated 155 
(1//⊕⊕OO); for women with a uterus, we recommend a progestogen (for example, progesterone 156 
and dydrogesterone) that is neutral on coagulation parameters. (1|⊕⊕⊕O) 157 
Breast Cancer  158 
3.1f For women considering MHT for menopausal symptom relief, we suggest evaluating the 159 
baseline risk of breast cancer and taking this risk into consideration when advising for or against 160 
MHT and when selecting type, dose, and route of administration. (2|⊕⊕OO) 161 
3.1g For women at high or intermediate risk of breast cancer considering MHT for menopausal 162 
symptom relief, we suggest non-hormonal therapies over MHT to alleviate bothersome VMS. 163 
(2|⊕⊕OO) 164 
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Tailoring Menopausal Hormone Therapy 165 
3.1h We suggest a shared decision-making approach to decide about the choice of formulation; 166 
starting dose; the route of administration of MHT; and how to tailor MHT to each woman’s 167 
individual situation, risks, and treatment goals. (Ungraded best practice statement) 168 
Custom-compounded Hormones 169 
3.1i We recommend using MHT preparations approved by the FDA and comparable regulating 170 
bodies outside the U.S., and recommend against the use of custom-compounded hormones. 171 
(Ungraded best practice statement) 172 
Conjugated Equine Estrogens with Bazedoxifene  173 
3.2 For symptomatic postmenopausal women with a uterus and without contraindications, we 174 
suggest the combination of conjugated equine estrogens (CEE)/bazedoxifene (BZA) (where 175 
available) as an option for relief of VMS and prevention of bone loss. (2|⊕⊕⊕O) 176 
3.3 Tibolone  177 
3.3a For women with bothersome VMS and climacteric symptoms and without 178 
contraindications, we suggest tibolone (in countries where available) as an alternative to MHT. 179 
(2|⊕⊕OO) 180 
3.3b We recommend against adding tibolone to other forms of MHT. (1|⊕⊕OO) 181 
3.3c We recommend against using tibolone in women with a history of breast cancer. (1|⊕⊕OO) 182 
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3.4 Clinical Management of Patients Taking Hormone Therapies 183 
Monitoring During Therapy 184 
3.4a For women with persistent unscheduled bleeding while taking MHT, we recommend 185 
evaluation to rule out pelvic pathology, most importantly, endometrial hyperplasia and cancer. 186 
(1|⊕⊕⊕O)  187 
3.4b We recommend informing women about the possible increased risk of breast cancer during 188 
and after discontinuing estrogen plus progestogen therapy and emphasizing the importance of 189 
adhering to age-appropriate breast cancer screening. (1|⊕⊕⊕O) 190 
3.4c We suggest that the decision to continue MHT be revisited at least annually, targeting the 191 
shortest total duration of MHT consistent with the treatment goals and evolving risk assessment 192 
of the individual woman. (Ungraded best practice statement) 193 
3.4d For young women with primary ovarian insufficiency, premature, or early menopause, 194 
without contraindications, we suggest taking MHT until the time of anticipated natural 195 
menopause, when the advisability of continuing MHT can be reassessed. (2|⊕⊕OO) 196 
Stopping Considerations  197 
3.4e For women preparing to discontinue MHT, we suggest a shared decision-making approach 198 
to elicit individual preference about adopting a gradual taper versus abrupt discontinuation. 199 
(2|⊕⊕OO) 200 
 Confidential.  JCEM Submission 4 REVISED                     May 7, 2015; July 17 2015; August 11, 2015;  
                                                                      August 19, 2015                                                                                                                        
 
11 
 
4.0 Non-hormonal Therapies for VMS  201 
4.0 For postmenopausal women with mild or less bothersome hot flashes, we suggest a series of 202 
steps that do not involve medication, such as turning down the thermostat, dressing in layers, 203 
avoiding alcohol and spicy foods, and reducing obesity and stress. (2|⊕⊕OO) 204 
4.1 Non-hormonal Prescription Therapies for VMS 205 
4.1a For women seeking pharmacological management for moderate to severe VMS for whom 206 
MHT is contraindicated, or who choose not to take MHT, we recommend SSRIs /SNRIs or 207 
gabapentin or pregabalin (if there are no contraindications). (1|⊕⊕⊕O) 208 
4.1b For those women seeking relief of moderate to severe VMS who are not responding to or 209 
tolerating the non-hormonal prescription therapies, selective serotonin reuptake inhibitors 210 
(SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs) or gabapentin or pregabalin, we 211 
suggest a trial of clonidine (if there are no contraindications). (2|⊕⊕OO) 212 
4.2 Over-the-Counter and Alternative Nonhormonal Therapies for VMS  213 
4.2 For women seeking relief of VMS with over-the-counter (OTC) or complementary medicine 214 
therapies, we suggest counseling regarding the lack of consistent evidence for benefit for 215 
botanicals, black cohosh, omega-3-fatty acids, red clover, vitamin E, and mind/body alternatives 216 
including anxiety control, acupuncture, paced breathing, and hypnosis. (2|⊕⊕OO) 217 
5.0 Treatment of Genitourinary Syndrome of Menopause   218 
5.1 Vaginal Moisturizers and Lubricants 219 
5.1a For postmenopausal women with symptoms of vulvovaginal atrophy (VVA), we suggest a 220 
trial of vaginal moisturizers to be used at least twice weekly. (2|⊕⊕OO) 221 
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5.1b For women who do not produce sufficient vaginal secretions for comfortable sexual 222 
activity, we suggest vaginal lubricants. (2|⊕⊕OO) 223 
5.2 Vaginal Estrogen Therapies 224 
5.2a For women without a history of hormone- (estrogen) dependent cancers who are seeking 225 
relief from symptoms of genitourinary syndrome of menopause (GSM) (including VVA) that 226 
persist despite using vaginal lubricants and moisturizers, we recommend low-dose vaginal 227 
estrogen therapy. (1|⊕⊕⊕O) 228 
Practice Statement  229 
 5.2b In women with a history of breast or endometrial cancer, who present with symptomatic 230 
GSM (including VVA), that does not respond to non-hormonal therapies, we suggest a shared 231 
decision-making approach that includes the treating oncologist to discuss using low-dose vaginal 232 
ET. (Ungraded best practice statement) 233 
5.2c For women taking raloxifene, without a history of hormone- (estrogen) dependent cancers, 234 
who develop symptoms of GSM (including VVA) that do not respond to non-hormonal 235 
therapies, we suggest adding low-dose vaginal ET. (2|⊕⊕OO) 236 
5.2d For women using low-dose vaginal estrogen therapy, we suggest against adding a 237 
progestogen (i.e., no need for adding progestogen to prevent endometrial hyperplasia). 238 
(2|⊕OOO) 239 
5.2e For women using vaginal estrogen therapy who report postmenopausal bleeding or spotting, 240 
we recommend prompt evaluation for endometrial pathology. (1|⊕⊕OO) 241 
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5.3 Ospemifene 242 
5.3a For treatment of moderate to severe dyspareunia associated with vaginal atrophy in 243 
postmenopausal women without contraindications, we suggest a trial of ospemifene. (2|⊕⊕⊕O) 244 
5.3b For women with a history of breast cancer presenting with dyspareunia, we recommend 245 
against ospemifene. (1|⊕OOO) 246 
 247 
 248 
 249 
 250 
 251 
  252 
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Method of Development of Evidence-based Clinical Practice Guidelines  253 
The Clinical Guidelines Subcommittee (CGS) of The Endocrine Society deemed management of 254 
menopause a priority area in need of a practice guideline and appointed a Task Force to 255 
formulate evidence-based recommendations. The Task Force followed the approach 256 
recommended by the Grading of Recommendations, Assessment, Development, and Evaluation 257 
(GRADE) group, an international group with expertise in development and implementation of 258 
evidence-based guidelines (1). A detailed description of the grading scheme has been published 259 
elsewhere (2). The Task Force used the best available research evidence to develop the 260 
recommendations. The Task Force commissioned three systematic reviews of the literature to 261 
inform its key recommendations. The Task Force used consistent language and graphical 262 
descriptions of both the strength of a recommendation and the quality of evidence using the 263 
recommendations of the GRADE system. In terms of the strength of the recommendation, strong 264 
recommendations use the phrase “we recommend” or “we recommend against” and the number 265 
1, and weak recommendations use the phrase “we suggest” or “we suggest against” and the 266 
number 2. Cross-filled circles indicate the quality of the evidence, such that ⊕OOO denotes very 267 
low quality evidence; ⊕⊕OO, low quality; ⊕⊕⊕O, moderate quality; and ⊕⊕⊕⊕, high quality. 268 
The Task Force has confidence that persons who receive care according to the strong 269 
recommendations will derive, on average, more good than harm. Weak recommendations require 270 
more careful consideration of the person’s circumstances, values, and preferences to determine 271 
the best course of action. Linked to each recommendation is a description of the evidence and the 272 
values the panelists considered when making the recommendation. In some instances, there are 273 
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remarks, a section in which panelists offer technical suggestions for testing conditions, dosing, 274 
and monitoring. These technical comments reflect the best available evidence applied to a typical 275 
person being treated. Often this evidence comes from the unsystematic observations of the 276 
panelists and their values and preferences; therefore, these remarks should be considered 277 
suggestions. In this guideline, the task force made several statements to emphasize the 278 
importance of shared decision making, general preventive care measures, and basic principles of 279 
women’s health. These were labeled as ungraded best practice statements. Direct evidence for 280 
these statements was either unavailable or not systematically appraised and considered out of the 281 
scope of this guideline. The intention of these statements is to draw attention and remind 282 
providers of these principles and these statements should not be considered as graded 283 
recommendations (3). 284 
The 2013 Appraisal of Guidelines for Research and Evaluation II (AGREEII) criteria (23 items) 285 
were satisfied, with 3 exceptions.  Item 5 stipulates that the views and preferences of the target 286 
population (patients, public, etc) have been sought.  We did not conduct specific polling/outreach 287 
to the public in anticipation of this guideline.  Item 14 states that a procedure for updating the 288 
guideline is provided.  This process has not been formalized.  Item 20 suggests that the potential 289 
resource implications of applying the recommendations have been considered.  We did not 290 
include cost analysis of risk assessment tools or prescription drug therapies.  291 
The Endocrine Society maintains a rigorous conflict-of-interest review process for the 292 
development of clinical practice guidelines. All Task Force members must declare any potential 293 
conflicts of interest, which are reviewed before the members are approved to serve on the Task 294 
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Force and periodically during the development of the guideline. The conflict-of-interest forms 295 
are vetted by the CGS before the members are approved by the Society’s Council to participate 296 
on the guideline Task Force. Participants in the guideline development must include a majority 297 
of individuals without conflict of interest in the matter under study. Participants with conflicts of 298 
interest may participate in the development of the guideline but they must have disclosed all 299 
conflicts. The CGS and the Task Force have reviewed all disclosures for this guideline and 300 
resolved or managed all identified conflicts of interest.  301 
Conflicts of interest are defined by remuneration in any amount from the commercial interest(s) 302 
in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, 303 
stock options, or ownership interest excluding diversified mutual funds); honoraria or other 304 
payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other 305 
financial benefits. Completed forms are available through the Endocrine Society office. 306 
Funding for this guideline was derived solely from the Endocrine Society, and thus the Task 307 
Force received no funding or remuneration from commercial or other entities. 308 
 309 
Commissioned Systematic Reviews 310 
The Task Force formulated three questions for systematic reviews to provide evidence 311 
supporting this guideline. The first compared the effect of oral versus transdermal estrogens on 312 
the risk of venous and arterial thrombotic events. Low quality evidence derived from 14 313 
observational studies suggested that, compared with transdermal menopausal hormone therapy 314 
(MHT), oral MHT was associated with increased risk of venous thromboembolism (VTE), deep 315 
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vein thrombosis (DVT), and possibly stroke, but not myocardial infarction (MI) (4). The second 316 
question evaluated the effect of MHT on mortality. Data from 43 randomized controlled trials 317 
(RCTs) demonstrated no association between all-cause mortality, regardless of hormone type, 318 
the presence of pre-existing heart disease, or length of follow-up (4), but data were insufficient to 319 
stratify by age or duration of menopause. The third question compared the effect of MHT with 320 
natural progesterone versus synthetic progestins on breast cancer risk. Low-quality evidence 321 
from two observational studies suggested that natural progesterone may be associated with a 322 
reduced risk for breast cancer compared with synthetic progestins, but data were insufficient to 323 
draw a firm conclusion (5).  324 
 325 
Introduction and Background  326 
Vasomotor symptoms (VMS), hot flashes, and night sweats, are the hallmarks of menopause, 327 
although not all women experience these symptoms. Other climacteric symptoms include sleep 328 
disturbance (6,7), arthralgia (7-9), and vaginal dryness and dyspareunia (7,10,11). It is less clear 329 
whether anxiety, irritability, depression, palpitations, skin dryness, loss of libido, and fatigue can 330 
be attributed to menopause (7,9,12). Symptoms frequently start in the years before the final 331 
menstrual period and can last, with unpredictable duration, from a few years to more than 13 332 
years (13-16). 333 
Estrogen therapy (ET) has long been recognized as the most effective treatment for the relief of 334 
bothersome vasomotor and vaginal symptoms associated with menopause. However, 335 
prescriptions for MHT declined considerably following the 2002 publication of the Women’s 336 
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Health Initiative (WHI) RCT. This study determined that for postmenopausal women, average 337 
age 63 years, oral conjugated equine estrogens (CEE) alone after hysterectomy, (17) or coupled 338 
with daily medroxyprogesterone acetate (MPA) in women with a uterus (18), was associated 339 
with risks disproportionate to preventive benefits (17,18). During ensuing years, a consensus 340 
arose that most healthy symptomatic women, without contraindications, closer to the time of 341 
menopause (< 10 years after menopause onset or age < 60 years) were appropriate candidates for 342 
MHT for symptom relief (19,20). Post hoc WHI analyses and observational data suggest that 343 
benefits exceed risks in the majority of these women. At this juncture, women in the United 344 
States (U.S.) and some other countries have a broader range of therapeutic choices than ever 345 
before, including: MHT dose, type, and route of administration; new selective estrogen receptor 346 
modulators (SERMs) as solo or combination therapies; and expanded choices of nonhormonal 347 
prescription medications. In this guideline, we emphasize safety in identifying which late 348 
perimenopausal and recently postmenopausal women are candidates for various therapeutic 349 
agents. Considerations include the risks and benefits of each available therapy, the expected 350 
duration of treatment, the intensity of monitoring during therapy, and most importantly, 351 
individualizing the course of therapy to reflect the specific characteristics of the patient who is 352 
making decisions regarding symptom management.  353 
This guideline covers the full spectrum of therapies for relief of the most common and 354 
bothersome menopausal symptoms (Figure 1). (The detailed management of early menopause 355 
transition, primary ovarian insufficiency, and prevention of osteoporosis and fracture are 356 
considered beyond the current scope.) Choice of therapy is ideally based on available evidence 357 
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regarding safety and efficacy and is generally a shared decision including both patient and 358 
provider. The treatment selected should be tailored to the individual patient and will vary 359 
according to each woman’s symptom severity, age, medical profile, personal preference, and 360 
estimated benefit/risk ratio. The impact of severe menopausal symptoms on quality of life (QOL) 361 
can be substantial, and there are instances in which a woman with a history of coronary heart 362 
disease or breast cancer, for example, will choose to accept a degree of risk that might otherwise 363 
be considered to outweigh the benefits of MHT. An accepted philosophy is that a fully informed 364 
patient should be empowered to make a decision that best balances individual QOL benefits 365 
against potential health risks (21). 366 
 367 
1.0 Diagnosis and Symptoms of Menopause 368 
1.1 We suggest diagnosing menopause based on the clinical criteria of the menstrual cycle. 369 
(2|⊕⊕OO) 370 
 371 
1.2 If establishing a diagnosis of menopause is necessary for patient management in women 372 
having undergone a hysterectomy without bilateral oophorectomy or presenting with a menstrual 373 
history that is inadequate to ascertain menopausal status, we suggest making a presumptive 374 
diagnosis of menopause based on the presence of VMS and, when indicated, laboratory testing 375 
that includes replicate measures of follicle stimulating hormone (FSH) and serum estradiol. 376 
(2|⊕⊕OO) 377 
  378 
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Technical Remark  379 
Table 1. summarizes other etiologies of secondary amenorrhea to be considered in the 380 
differential diagnosis. 381 
 382 
Diagnosis 383 
Table 1 lists definitions of the clinical spectrum of menopause. In a woman with an intact uterus, 384 
menopause is a clinical diagnosis based upon cessation of menses for at least 12 months. Sex 385 
steroids, gonadotropins, inhibin B, or anti-Mullerian hormone (AMH) measurements do not 386 
further inform the diagnosis, do not indicate precisely when the final menstrual period will occur, 387 
and will not influence management unless a woman is seeking fertility. In women having 388 
undergone a hysterectomy but not bilateral oophorectomy, elevated FSH levels and estradiol 389 
concentrations < 20 pg/ml on several occasions support but do not confirm the diagnosis. A 390 
distinction between the late perimenopause transition, marked by episodes of > 60 days of 391 
amenorrhea and increasing severity of VMS (15), and early postmenopause cannot be made on 392 
the sole basis of hormone measurements. With radiotherapy- or chemotherapy-induced 393 
menopause, it is important to recognize that ovarian function may resume after 12 months of 394 
amenorrhea (22), depending on the age of the woman and the dose and duration of treatment 395 
(22). For primary ovarian insufficiency (POI), persistent FSH elevation in women < age 40 396 
provides a tentative diagnosis (Table 1).  397 
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Signs and Symptoms  398 
Vasomotor Symptoms   399 
Prevalence. Hot flashes (also called hot flushes) occur in approximately 75% of postmenopausal 400 
women in the U.S. (23). In the Study of Women Across the Nation (SWAN), after controlling for 401 
age, education, health, and economic strain, researchers found that U.S. Caucasian women report 402 
more psychosomatic symptoms, African-American and Hispanic women more VMS, and Asian 403 
women more somatic complaints (16,24). Notably, across countries and ethnic backgrounds, the 404 
percentage of women reporting hot flashes varies (25-27). In a cross-sectional study of 405 
premenopausal women mean aged 48 years, one third reported ‘ever’ experiencing hot flashes 406 
(28). A comparison between VMS experienced during the premenopause versus the 407 
postmenopause may be informative when counseling a postmenopausal woman regarding 408 
symptom relief, although to our knowledge, the presence and frequency of premenopausal hot 409 
flashes have not been studied as being predictive of response to therapy in the postmenopause. 410 
Persistence of hot flashes may also vary depending upon when in the menopausal transition 411 
VMS were first noted. In SWAN, earlier onset of VMS was associated with longer 412 
postmenopausal duration (16).   413 
 414 
Clinical Manifestations. Hot flashes typically begin as the sudden sensation of heat centered on 415 
the upper chest and face. When moderate or severe, the hot flash rapidly becomes generalized, 416 
lasts from 2 to 4 minutes, and can be associated with profuse perspiration, palpitations, or 417 
anxiety. Triggers include spicy food or alcohol. At night, vasomotor instability manifests as hot 418 
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flashes or night sweats, which may represent different physiological mechanisms. The 419 
differential diagnosis includes several entities distinguishable by clinical features (Table 2). 420 
New-onset VMS in older (> age 65) postmenopausal women may be associated with, but not 421 
necessarily causally related to, increased risk of major coronary heart disease (CHD) and all-422 
cause mortality (29). 423 
 424 
Association with Sleep. In polysomnography studies, nocturnal hot flashes are more common 425 
during the first 4 hours of sleep, whereas subsequent rapid eye movement (REM) sleep 426 
suppresses hot flashes, arousals, and awakenings (30). A recent study that induced estrogen 427 
deficiency in healthy premenopausal women with a gonadotropin-releasing hormone agonist 428 
directly demonstrated that hot flashes are associated with three factors: (1) an increase in 429 
episodes of waking after sleep-onset, (2) a decrease in perceived sleep efficiency, and (3) a 430 
statistically significant correlation between nocturnal VMS and sleep disruption (31). While 431 
these data are informative, it has not been substantiated whether they apply in naturally 432 
postmenopausal women with continuously high gonadotropins. An important contributing factor 433 
is aging, which likely is also involved in sleep disturbances in menopausal women.  434 
 435 
Mechanisms. VMS appear to involve the central nervous system (CNS) (32) because: (1) hot 436 
flashes occur simultaneously with, but are not caused by, LH pulses (33,34), and (2) research has 437 
shown an association with the neuroregulators kisspeptin, neurokinin B, and dynorphin (35). 438 
Alterations of thermoregulatory systems are mechanistically involved, as women with hot flashes 439 
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exhibit a narrowing of the thermoregulatory-neutral zone (32). Whereas premenopausal women 440 
initiate mechanisms to dissipate heat when the core body temperature increases by 0.4° C, this 441 
happens with much lower increases in temperature in menopausal women (36). Core body 442 
temperature is usually still within the normal range at the onset of the flash, but inappropriate 443 
peripheral vasodilatation with increased digital and cutaneous blood flow and perspiration results 444 
in rapid heat loss and a fall in core body temperature (32). Shivering may occur to restore the 445 
core temperature (36).  446 
 447 
Genitourinary Syndrome of Menopause 448 
This new term genitourinary syndrome of menopause (GSM) combines the conditions of 449 
vulvovaginal atrophy (VVA) and urinary tract dysfunction (Table 3) (37). VVA most often 450 
presents in the late postmenopausal stage, when VMS may have abated (15). When VVA is 451 
severe, women may have discomfort wearing tight-fitting clothing or while sitting and 452 
exercising. Sexual activity is not required for patients to experience vaginal or genital 453 
discomfort. Urinary symptoms—dysuria, urinary frequency, and recurrent urinary tract 454 
infections—increase in severity with time since menopause.  455 
 456 
Other Signs and Symptoms  457 
The menopausal decline of estradiol increases bone resorption and contributes to fractures (38).  458 
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 459 
Possible Related Signs and Symptoms  460 
Research has suggested (but not proven) a direct relationship between menopause and mood 461 
changes, mild depressive symptoms, anxiety, irritability, arthralgias, loss of libido, palpitations, 462 
skin dryness, fatigue, and reduction in QOL (38,39). As opposed to the conclusions in the 2005 463 
National Institutes of Health State of the Science consensus regarding the uncertain relationship 464 
between mood and menopause, more recent longitudinal studies now support an association of 465 
the menopause transition with depressed mood, major depressive episodes, and anxiety (46).   466 
 467 
2.0 Health Considerations for All Menopausal Women  468 
2.1 When women present during the menopausal transition, we suggest using this opportunity to 469 
address bone health, smoking cessation, alcohol use, cardiovascular risk assessment and 470 
management, and cancer screening and prevention. (Ungraded best practice statement) 471 
 472 
Evidence 473 
The menopause transition, a portal to the second half of life, is a critical window to reassess 474 
lifestyle, recognize ongoing and potential health concerns, and encourage a proactive approach to 475 
future well-being, regardless of menopausal symptoms. In order to decrease morbidity and 476 
mortality from cardiovascular disease (CVD) and cancer and maintain QOL, optimizing diet and 477 
exercise to maintain healthy weight are important measures, as are counseling regarding alcohol 478 
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use and smoking cessation and identifying and treating hypertension, glucose intolerance, and 479 
dyslipidemias (40,41).  480 
 481 
Adequate intake of calcium and vitamin D, along with limiting alcohol consumption will 482 
minimize bone loss and reduce the risk of falls and fractures (42). For postmenopausal women < 483 
65 years of age and at high risk of osteoporosis, dual-energy x-ray absorptiometry assessment of 484 
bone mineral density contributes to risk assessment. ET for the relief of menopausal symptoms 485 
prevents bone loss and reduces fracture risk (43). Women without VMS and at significant risk of 486 
osteoporosis can discuss merits of ET for bone preservation. Recent guidelines address bone-487 
specific therapies (43).  488 
 489 
3.0 Hormone Therapy for Menopausal Symptom Relief  490 
3.1 Estrogen and Progestogen Therapy 491 
3.1a For menopausal women < 60 years of age or < 10 years past menopause with bothersome 492 
VMS (with or without additional climacteric symptoms) who do not have contraindications or 493 
excess cardiovascular or breast cancer risks and are willing to take MHT, we suggest initiating 494 
ET for those without a uterus, and estrogen plus progestogen therapy (EPT) for those with a 495 
uterus. (2|⊕⊕OO) 496 
Evidence 497 
In postmenopausal women, ET improves menopause-associated (climacteric) symptoms (e.g., 498 
VMS, genitourinary symptoms, sleep disturbance, menopause-associated anxiety and depressive 499 
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symptoms, and arthralgias). ET also reduces menopause-related bone loss, lowers the risk of 500 
fragility fractures in older women, and reduces the incidence of self-reported diabetes. In 501 
addition, combined EPT reduced the risk of colorectal cancer and, in cumulative follow-up of the 502 
WHI, endometrial cancer (38,44). 503 
MHT is not appropriate for all symptomatic menopausal women (Figure 2). There are no 504 
commonly recognized lists of absolute or relative contraindications to MHT as published in 505 
professional society guidelines. And while U.S. product labeling (regulated by the U.S. Food and 506 
Drug Administration (FDA]) does include contraindications to MHT (Table 4), caution is also 507 
advised for women with certain additional medical conditions (Table 4). Risk/benefit assessment 508 
is the most important consideration, and QOL may be an important issue in a decision to 509 
recommend MHT. Women with conditions precluding MHT (Table 4), who are unwilling to take 510 
MHT, or at substantial risk for breast cancer or cardiovascular disease can consider nonhormonal 511 
options for symptom relief (Section 4.0). 512 
 513 
Risks and Benefit Overview  514 
Healthcare providers and patients should choose MHT based on individual risks and benefits 515 
utilizing a shared decision-making approach. Current recommendations suggest that the initiation 516 
of MHT should generally be limited to women < 60 years of age or < 10 years after menopause 517 
onset. Accordingly, data are needed to estimate risks and benefits in this specific population. No 518 
adequately powered RCTs with clinical outcomes have been specifically conducted with 519 
younger, symptomatic women, however, and data for women < 50 years old are limited. The best 520 
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available evidence comes from subgroup analyses of WHI data, which provide information 521 
specifically in women 50 to 59 years of age or < 10 years since menopause onset. Because of the 522 
number of women participants ages 50 to 59 (5,520 in the combined therapy arm and 3,313 in 523 
the estrogen-alone arm), and the low event rate for MI and stroke in this age group, such data 524 
provide trends but few statistically significant differences. Findings from observational studies, 525 
case reports, and clinical expertise, both from the U.S. and other countries, provide additional 526 
sources of evidence regarding younger postmenopausal women.   527 
Estimations of risks and benefits previously published in the Endocrine Society’s 2010 Scientific 528 
Statement utilized both observational and RCT data. However, updated outcomes from the WHI 529 
are now available. Accordingly, the updated reanalysis of the WHI (44) is considered by many to 530 
provide the best available data on risks and benefits in women ages 50 to 59, but not in those 531 
younger than age 50. The 2010 Statement expresses attributable (excess) benefits and risks as the 532 
number of affected women/1,000 users/5 years of therapy, assuming that most women initiating 533 
MHT will consider therapy for 5 years. Maintaining this format, the risks and benefits (as 534 
reported in the WHI and reflecting the specific oral therapies studied) are presented in Figure 3 535 
and are not repeated in the text of this guideline. These data, representing the effects of CEE with 536 
or without MPA, cannot be extrapolated to other MHT regimens. However, in the absence of 537 
RCTs with other specific agents, they provide the most conservative estimates. Notably, the 538 
baseline risk of most adverse events is lower in younger versus older women and results in lower 539 
attributable risk even though relative risks may be similar among various age groups. The 540 
converse is also true for benefits, such as fracture reduction.  541 
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 542 
Benefits of Menopausal Hormone Therapy 543 
Vasomotor Symptoms 544 
ET is the most effective treatment for VMS and improving QOL in symptomatic women (38). In 545 
a dose-dependent manner, MHT reduces hot flash frequency by approximately 75% and severity 546 
by 87%, compared with 50% with placebo (38,45,46).  547 
 548 
Genitourinary Syndrome of Menopause 549 
Systemic estrogen administration effectively treats VVA and improves symptoms of overactive 550 
bladder and recurrent urinary tract infections (47,48). With lower doses of systemic MHT, 551 
vaginal symptoms may persist and local therapy may be needed (Section 5).  552 
 553 
Sleep Disruption 554 
Large placebo-controlled trials reported significantly fewer sleep disturbances with MHT use 555 
(44), but additional data are required for definitive conclusions.  556 
Anxiety and Depressive Symptoms 557 
Anxiety symptoms increase during the menopause transition, and are associated with an 558 
increased likelihood of a major depressive disorder (49). ET may improve mild-to-moderate 559 
depressive symptoms during or shortly after the menopause transition, while antidepressant 560 
therapy remains appropriate treatment for major depression (50,51). 561 
 Confidential.  JCEM Submission 4 REVISED                     May 7, 2015; July 17 2015; August 11, 2015;  
                                                                      August 19, 2015                                                                                                                        
 
29 
 
 562 
Arthralgia  563 
Joint pain or stiffness and general aches or pains were improved in women receiving EPT 564 
(38,44,52). Joint pain increased slightly after discontinuation of treatment (44).  565 
 566 
Potential Preventive Benefits of Menopausal Hormone Therapy 567 
 While studies have suggested certain preventive benefits, the U.S. Preventive Services Task 568 
Force (53) and many expert groups (40,54-56) recommend against MHT for primary or 569 
secondary disease prevention, whereas other experts disagree (57).  570 
 571 
Bone Loss and Fracture. RCTs, observational studies, and meta-analyses consistently report 572 
reduction in bone loss with ET (38). The updated WHI analysis reports a significant reduction in 573 
vertebral fractures and a borderline significant reduction for all fractures with EPT in women 574 
ages 50 to 59 (Figure 3); this effect was greater than with ET (44). Benefit may also be dose 575 
related (38).  576 
Type 2 Diabetes. RCTs (58-60) and large observational studies (61,62) reported that MHT 577 
reduced the prevalence of self-reported diabetes by 14 to 19% (44), an effect that did not persist 578 
after therapy was discontinued (44).  579 
 580 
Colorectal Cancer. In clinical trials, EPT was associated with a nonsignificant lower incidence 581 
of colorectal cancer in women age 50 to 59 (63). Cancers that did occur in women receiving 582 
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EPT, however, were diagnosed at a more advanced stage when all age groups were considered 583 
(64). The reduction in cancer during active therapy did not persist after discontinuation (44). 584 
 585 
Endometrial Cancer. During 13 years of cumulative follow-up of the WHI, combined CEE and 586 
MPA was associated with a 35% reduction in endometrial cancer in women ages 50 to 59 (HR, 587 
0.65; 95% CI, 0.37-1.12) (44). This finding may be unique to the specific type, dose, and 588 
regimen utilized.  589 
 590 
Risks of Menopausal Hormone Therapy 591 
Endometrial Cancer 592 
Unopposed ET increases the risk of endometrial hyperplasia and cancer (38,65,66), whereas 593 
concurrent progestogen therapy (Table 5) for at least 12 days per month reduces this risk 594 
(18,44,67) and is recommended for all women with a uterus. Continuous combined CEE and 595 
MPA was associated with a reduced risk of endometrial cancer over 13 years of cumulative 596 
follow-up (44). After 6 to 10 years, sequential regimens may be associated with a 2-fold 597 
increased risk of endometrial cancer, particularly in thin women (38). Micronized progesterone 598 
and dydrogesterone, in combination with estrogen, have been associated with an approximate 2-599 
fold increase in endometrial cancer when continued beyond 5 years in a large observational study 600 
(68). In contrast, one RCT comparing micronized progesterone with MPA (3 years) (69), a 601 
second RCT comparing micronized progesterone with chlormadinone acetate (18 months) (70), 602 
and a third trial of single-tablet formulation of cyclical estradiol-dydrogesterone (2-years), each 603 
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demonstrated endometrial safety (71). The difference in outcome may reflect enhanced patient 604 
compliance with progestogen therapies when formulated in combination. Limited information is 605 
available about safety of long cycle intermittent use of progestogens, but concern has been raised 606 
about increased risk of endometrial cancer (72,73). 607 
The levonorgestrel intrauterine device (not approved for a postmenopausal indication in the U.S. 608 
but widely used in other countries and, increasingly, off-label in U.S.) appears effective at 609 
minimizing hyperplasia and endometrial cancer risk, especially in obese women (74-76). 610 
 611 
Breast Cancer 612 
Estrogen Therapy. The majority of, but not all, observational studies report an increased breast 613 
cancer risk with oral or transdermal estradiol when initiated in recently menopausal women (77-614 
79). This increase occurs as a function of duration of ET (38,80-82) with a linear trend in the 615 
largest study (83). Insufficient numbers of patients may confound the interpretation of these data 616 
on ET alone (i.e., type II statistical error). It is possible that in observational studies 617 
mammographic surveillance differed between users and nonusers of MHT. The finding  of 618 
increased risk in recently menopausal women is controversial, however. In women in the WHI 619 
ages 50 to 59 or < 10 years after menopause onset, CEE did not increase risk (44,84). The 620 
statistically significant 21% reduction of invasive breast cancer in the 13-year cumulative follow-621 
up of all women in the estrogen-alone arm of the WHI was of similar magnitude in each age 622 
group (44), but some analyses have suggested less reduction or increase in risk among women 623 
starting ET close to menopause (77,85).  624 
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The presence or absence of obesity confounds the interpretation of existing data. The aromatase 625 
enzyme, which increases with obesity, results in enhanced endogenous estrogen production, 626 
which may minimize the additional effects of exogenous ET. The insulin resistance associated 627 
with obesity also confounds the relationship between obesity and breast cancer risk (86). 628 
Therefore, increased breast cancer risk with ET in non-U.S. studies might reflect differing levels 629 
of obesity between U.S. and European populations. CEE and estradiol may also have differential 630 
effects as suggested by in vitro (87) and primate (88) studies. In summary, the risk of breast 631 
cancer from estrogen alone, taken for 5 years, appears to be small. 632 
 633 
Combined Estrogen Plus Progestogen Therapy. Studies examining the effects of combined 634 
therapy report a consistent increase in breast cancer risk (38,89,90). It should be noted that the 635 
original WHI study did not report any increase overall in women who had not previously used 636 
MHT (hormone naïve), but data on this issue are not available for women ages 50 to 59 or < 10 637 
years postmenopausal (18,91), and there are no reported follow-up data for the hormone-naïve 638 
women. In women ages 50 to 59 in the WHI, the excess risk of invasive breast cancer during the 639 
intervention phase persisted 7 years after the cessation of EPT, with 4.5 excess cases/1,000 over 640 
5 years (HR: 1.34; 95% CI, 1.03-1.75) (44). Studies have reported similar findings with most 641 
other estrogen/progestogen combinations (38,68,92). However, observational data suggest that 642 
progesterone or dydrogesterone (5,68) may be associated with a lower risk, but further studies 643 
are required to confirm this. Observational studies also report a greater risk when EPT is started 644 
close to menopause (79,85,93) and with continuous rather than with cyclic regimens (78,82,94).  645 
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 646 
Lung Cancer 647 
In the 50 to 59 year age group in the WHI study, the incidence of lung cancer was not 648 
significantly increased or decreased in either treatment arm (43).  649 
 650 
Ovarian Cancer 651 
 In the 50 to 59 year age group of the WHI, the hazard ratio of ovarian cancer with EPT was 0.30 652 
(2 vs. 6 cases; 95% CI, 0.06-1.47), with 1.5 fewer cases/1,000 per 5 years of treatment (44). No 653 
data have been reported for ET. A controversial meta-analysis of 52 observational studies (95-654 
97) showed an increase of 0.52 cases/1,000 in women starting MHT (no difference in risk 655 
between ET and EPT) at age 50 and continuing therapy for 5 years. Risk persisted 5 years after 656 
stopping MHT with 0.37 cases/1,000 in the same women when age 55 to 59 (95). Of note, the 657 
overall risk of ovarian cancer with EPT in the WHI (HR 1.41), although not statistically 658 
significant, was comparable to findings in the meta-analysis, as was the rate in the cumulative 659 
follow-up (HR 1.24). Based on current data, adequately powered RCTs are needed to fully 660 
ascertain ovarian cancer risk in symptomatic, recently postmenopausal women.  661 
 662 
Coronary Heart Disease  663 
Estrogen Therapy. The age at initiation of ET influences risk. In the WHI, there was a trend 664 
toward a reduction in coronary heart disease (CHD) and total MI in women aged 50 to 59 at trial 665 
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enrollment (63). Composite outcomes, including revascularization (98) and coronary artery 666 
calcium scores (99), were lower with ET than with placebo.  667 
 668 
Observational studies of ET suggest the potential for CHD benefit in some women, although a 669 
number of biases might have contributed to those conclusions (100). In summary, ET does not 670 
increase CHD risk in women starting therapy at ages < 60, and may possibly reduce this risk. 671 
 672 
While observational studies suggest that a dermal route of ET may carry a lower risk of MI 673 
(101,102), a meta-analysis reported no significant difference in CHD outcomes between oral and 674 
transdermal MHT (4). No associations with estrogen dose were reported (101,102).  675 
 676 
Combined Estrogen plus Progestogen Therapy. Age at initiation of EPT does not appear to 677 
influence the relative risk of CHD, based on the most recent WHI data (44) and a meta-analysis 678 
(4). In women in the WHI aged 50 to 59, there was a trend toward excess risk of CHD, but no 679 
increased risk was apparent in women < 10 years since menopause onset (44). These findings 680 
and those of several recent studies have been controversial. A randomized osteoporosis trial that 681 
did not have CHD as a predefined primary endpoint reported that 10 years of MHT treatment in 682 
women < 50 years at study onset was associated with reduction of a composite safety endpoint 683 
(death, hospital admission for MI, or heart failure) (103). This study has been criticized for its 684 
composite index and nonblinded nature. A primary prevention RCT of recently (< 3 years) 685 
postmenopausal women ages 42 to 58 failed to detect a difference in progression of 686 
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atherosclerosis (as assessed by carotid intima–medial thickness and coronary artery calcium 687 
determinations) after 4 years of therapy (104), but may have been underpowered to detect 688 
significant differences (i.e., Type II error). In summary, EPT does not appear to be associated 689 
with an increased risk of CHD among women close to the onset of menopause, and if any risk 690 
elevation is present in women younger than 60, its magnitude is small. A definitive conclusion 691 
regarding CHD risk requires an appropriately powered RCT. 692 
 693 
Stroke  694 
Researchers reported a non-significant trend toward an increase in stroke risk with EPT in 695 
women ages 50 to 59 in the WHI (44), but did not report an adverse effect with ET. When 696 
examined by years since menopause, ET increased stroke risk in women < 10 years since 697 
menopause (6.5 women/1,000 over 5 years) (44). The differences between these two groups 698 
might reflect the difficulty in establishing time of menopause in women with a hysterectomy.  699 
No RCTs have evaluated stroke risk according to estrogen type, dose, or route of administration. 700 
Some observational studies suggest that transdermal estradiol in doses < 50 mcg may confer a 701 
lower risk compared with higher dose transdermal or oral therapies (4,105). Other studies are 702 
conflicting regarding effects of estrogen type (102,106) and dose (101,105,107). In summary, 703 
MHT may confer a small risk of stroke.  704 
 705 
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Venous Thromboembolic Events  706 
Estrogen Therapy. RCTs demonstrate that oral ET increases VTE risk in women ages 50 to 59 707 
(44). These data are supported by observational studies (18,106,108,109). Risk declined after 708 
discontinuing therapy (44). Observational studies (108-112) and meta-analyses (4,113) suggest 709 
that transdermal ET does not increase VTE risk, even in women with thrombophilia or obesity 710 
(114-117). In an observational study, oral CEE was associated with 2-fold increase VTE 711 
compared with oral estradiol (106). 712 
 713 
Combined Estrogen plus Progestogen Therapy. The WHI trial found an association between 714 
EPT and both DVT and pulmonary embolism in women ages 50 to 59 (44). Risks resolved when 715 
therapy was discontinued. Observational studies suggest that formulations containing 716 
medroxyprogesterone acetate (MPA) and normethytestosterone derivatives appear to be 717 
associated with greater risk than other progestogens (108,109,111). A recent meta-analysis 718 
comparing ET and EPT did not report any statistically significant differences in risk (4).  719 
 720 
Gallbladder Disease 721 
No data are available specifically for women ages 50 to 59; conclusions regarding gallbladder 722 
disease rely on overall findings of the WHI. ET resulted in 29 excess cases/1,000 women over 5 723 
years (44). This risk did not persist after discontinuation (44,118). With EPT, the excess risk was 724 
23 women/1,000 (44), similar to another trial (119). Risk persisted at least 5 years after cessation 725 
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of EPT (44,120). Observational studies report increased risk with oral but not transdermal 726 
estradiol (121,122), and increased dose and duration (120,123).  727 
 728 
Incontinence 729 
Stress urinary incontinence, urge urinary incontinence, and mixed urinary incontinence increase 730 
in women taking oral ET and EPT (124,125). An increased risk may persist after discontinuation 731 
(44). 732 
 733 
Uncertain Benefits of Hormone Therapy  734 
Mortality  735 
A meta-analysis of RCTs demonstrated no significant effect on all-cause mortality with MHT 736 
use, but these data included women < and > 60 years of age (126). A recent Cochrane 737 
collaboration review reported a 30% relative risk reduction (HR 0.70; 0.52-0.95) of all-cause 738 
mortality in women starting MHT < 10 years since menopause (or < age 60) (127). Comparison 739 
of the ET and EPT groups in the WHI suggested a stronger trend by age group among those on 740 
ET, with a statistically significant trend by age in the ET, but not the EPT trial (44). 741 
Observational studies (128-130) reported a reduction in mortality with MHT, as did one small 742 
RCT with composite endpoints (103). This is consistent with meta-analyses that reported a 30 to 743 
40% mortality reduction (131,132). In summary, further data are required for definitive 744 
conclusions about mortality in younger women.  745 
 746 
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Dementia 747 
Observational studies suggest a possible benefit of MHT if started in younger women closer to 748 
menopause (133), as opposed to the detrimental effects reported in clinical trials when MHT is 749 
initiated in women > 65 years (134). Some studies of postmenopausal women treated with 750 
estradiol reported an improvement in verbal memory and executive function (15,80,135-138), 751 
whereas other studies did not associate CEE therapy with cognitive improvement (139,140). 752 
Definitive conclusions about MHT in women < age 60, therefore, are lacking.  753 
Individual Baseline Risk Assessment and Therapeutic Decisions  754 
Evaluating risk facilitates individual counseling and decisions regarding MHT for symptom 755 
relief (Figure 2). However, no clinical trial evidence is available to support the practice of 756 
incorporating risk assessment instruments for quantifying cardiovascular (CHD, stroke, and 757 
VTE) and breast cancer risks among women considering MHT. Nevertheless, we feel that risk 758 
assessment instruments are useful to facilitate decision-making regarding MHT.   759 
 760 
Cardiovascular Risk  761 
3.1b For women < age 60 or < 10 years past menopause onset considering MHT for menopausal 762 
symptom relief, we suggest evaluating the baseline risk of CVD and taking this risk into 763 
consideration when advising for or against MHT and when selecting type, dose, and route of 764 
administration. (2|⊕⊕OO)  765 
3.1c For women at high risk of CVD, we suggest initiating non-hormonal therapies to alleviate 766 
bothersome VMS (with or without climacteric symptoms) over MHT. (2|⊕⊕OO) 767 
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 768 
Technical Remarks   769 
High risk includes known MI, cerebrovascular disease, and peripheral arterial disease, etc.  770 
 771 
3.1d For women with moderate risk of CVD, we suggest transdermal estradiol as first-line 772 
treatment, alone for women without a uterus or combined with micronized progesterone (or 773 
another progestogen that does not adversely modify metabolic parameters) for women with a 774 
uterus, as these preparations have less untoward effect on blood pressure, triglycerides, and 775 
carbohydrate metabolism. (2|⊕⊕OO) 776 
 777 
Evidence 778 
Cardiovascular Risk 779 
Results showing fewer excess CHD and stroke events when MHT was initiated in younger rather 780 
than older study participants in the WHI (141) provide the foundation for the widely accepted 781 
consensus that MHT should be initiated primarily in younger women (< age 60 years) close in 782 
time (< 10 years) to menopause onset, when women likely have less baseline atherosclerosis 783 
(19,20). The population prevalence of obesity, hypertension, dyslipidemia, and diabetes 784 
continues to increase. Accordingly, baseline CVD risk evaluation is important in women 785 
considering MHT. As reviewed in recent statements, CHD and stroke are associated with a wide 786 
range of risk factors, many unique to women (40,41). Notably, a prior history of CHD conveys 787 
the highest risk of subsequent MI and stroke (142). We feel that methods to integrate these 788 
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factors to categorize individual risk as minimal, moderate, and high are useful and can be 789 
accomplished qualitatively by clinical judgment or quantitatively by risk assessment tools.  790 
Country- and population-specific CVD risk calculators are available to quantify individual risk 791 
per local guidelines (143). However, specific cut-offs for the safe use of MHT have not been 792 
formally validated, and practice differs from country to country.  793 
The Menopause Decision-Support Algorithm (63) starts with calculating the American College 794 
of Cardiology/American Heart Association (ACC/AHA) 10-year CVD risk (144), then stratifies 795 
by years since menopause to suggest appropriateness of MHT (Table 6) (63). For a woman at 796 
intermediate risk, family history, coronary artery calcium score, CRP, and ankle-brachial index 797 
can further stratify risk (144); inflammatory markers and lipid ratios predict treatment-related 798 
CHD events (145).  799 
 800 
The Metabolic Syndrome. The Metabolic Syndrome (MetS) is associated with higher risk of 801 
cardiovascular events and breast and colon cancers (146). In a nested case control study in the 802 
WHI, women with MetS at baseline were twice as likely to have CHD events while taking oral 803 
MHT as with placebo (147). In contrast, women without MetS had no increase in CHD risk on 804 
MHT. Transdermal estradiol with micronized progesterone might have less deleterious metabolic 805 
effects than oral therapies, but there are no RCT that have evaluated the safety of these 806 
preparations in women with MetS.  807 
 808 
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Diabetes. Diabetes is considered by the AHA to be a CHD risk equivalent (40), which would 809 
suggest that women with diabetes should not take MHT. However, clinical trial evidence of 810 
CVD outcomes associated with MHT in women with diabetes is mostly lacking. Some diabetic 811 
women were included in RCTs (Heart and Estrogen/Progestin Replacement Study [19%]; WHI 812 
[4.4-7.7%]), but these trials were not powered to assess differences in CVD outcomes. A few 813 
short-term RCTs have evaluated glucose control in diabetic women taking a variety of MHT 814 
preparations and showed either no effect or improved control (148). The evidence at this time is 815 
inadequate to make firm recommendations. An individualized approach to treating menopausal 816 
symptoms could be considered, with a low threshold to recommend non-hormonal therapies, 817 
particularly in women with concurrent cardiovascular disease. However, some diabetic women, 818 
after careful evaluation of cardiovascular risk, may be candidates for MHT, preferably 819 
transdermal estrogen and micronized progesterone or another less metabolically active 820 
progestogen.  821 
 822 
Venous Thromboembolic Events 823 
3.1e For women at increased risk of VTE who request MHT, we recommend a non-oral route of 824 
ET at the lowest effective dose, if not contraindicated (1//⊕⊕OO); for women with a uterus, we 825 
recommend a progestogen (for example, progesterone and dydrogesterone) that is neutral on 826 
coagulation parameters. (1|⊕⊕⊕O) 827 
 828 
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Evidence 829 
Obesity, age, and thrombophilia are associated with increased risk of VTE. An approximately 2-830 
fold increase risk of VTE (both DVT and pulmonary embolism) with oral MHT is similar among 831 
women at low, intermediate, or high risk (149,150). Accordingly, the attributable risk of MHT 832 
will be higher in those at high or intermediate baseline risk. 833 
A prior history of VTE confers the highest risk. If the patient has a known inherited coagulation 834 
defect, such as Factor V Leiden, oral ET or EPT should be avoided, as research has shown a high 835 
risk of VTE recurrence (114). A history of VTE due to pregnancy, oral contraceptives, unknown 836 
etiology, or blood clotting disorders poses a contraindication to any ET, whereas VTE due to 837 
past immobility, surgery, or bone fracture would be a contraindication to oral but not necessarily 838 
transdermal MHT (151). In some countries, a history of any VTE is a contraindication to oral but 839 
not low-dose transdermal ET.  840 
 841 
Breast Cancer  842 
3.1f For women considering MHT for menopausal symptom relief, we suggest evaluating the 843 
baseline risk of breast cancer and taking this risk into consideration when advising for or against 844 
MHT and when selecting type, dose, and route of administration. (2|⊕⊕OO) 845 
3.1g For women at high or intermediate risk of breast cancer considering MHT for menopausal 846 
symptom relief, we suggest non-hormonal therapies over MHT to alleviate bothersome VMS. 847 
(2|⊕⊕OO) 848 
 849 
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Technical Remarks 850 
High or intermediate risk includes calculated level of risk that would qualify for risk-reducing 851 
medications.  852 
 853 
Evidence 854 
There are no established clear criteria for recommending (or avoiding) MHT based on a 855 
woman’s risk of breast cancer. Non-significant trends from the WHI suggest that the relative risk 856 
of breast cancer in association with MHT remains stable or increases in the 5-year Gail model 857 
breast risk categories of < 1.25 versus ≥ 1.75. On this basis, the excess or attributable risk should 858 
increase in women at higher categories of risk (90,152). As another consideration, it seems 859 
prudent not to recommend MHT for women whose risk meets the criteria for breast cancer 860 
prevention with SERMs or aromatase inhibitors. The U.S. Preventive Services Task Force 861 
recommends that women with a 5-year risk of  > 3% should be considered for preventive therapy 862 
with tamoxifen or raloxifene (53), whereas the American Society of Clinical Oncology 863 
guidelines suggests discussing such therapy in women with a risk of  ≥ 1.67% (153) consistent 864 
with enrolment criteria of breast cancer prevention trials. Prevention recommendations differ 865 
outside the U.S. Another consideration is to take into account the data suggesting that breast 866 
cancer risk is associated with combined estrogen/progestogen  use but less so, if at all, with CEE 867 
alone. 868 
We suggest one potential algorithm for MHT counseling, extrapolated from breast cancer 869 
prevention trial enrolment criteria (Table 6); however, it is not validated in clinical trials or 870 
 Confidential.  JCEM Submission 4 REVISED                     May 7, 2015; July 17 2015; August 11, 2015;  
                                                                      August 19, 2015                                                                                                                        
 
44 
 
widely utilized. This algorithm requires the assessment of breast cancer risk, which can be 871 
accomplished by qualitative methods or preferably with readily available quantitative risk 872 
assessment tools. The National Cancer Institute Breast Cancer Risk Assessment Tool provides a 873 
standardized online risk calculator for 5-year risk of invasive breast cancer (154). The 874 
International Breast Intervention Study calculator predicts 10-year and lifetime risk (155,156). 875 
For women with strong family histories of breast cancer, several other methods are available 876 
(155). While these provide useful predictive information, all are limited by only moderate 877 
discriminatory accuracy (155). Mammographic breast density, when added to these methods, 878 
may emerge as an important objective risk for women contemplating MHT (157-159). 879 
Although a history of breast cancer is considered by most to be a contraindication to MHT, the 880 
severity of menopausal symptoms, the compromise in QOL experienced by breast cancer 881 
survivors, and limitations of non-hormonal therapies for relief of VMS present a persistent 882 
clinical challenge. As recently summarized, it is not possible from currently available studies to 883 
draw firm conclusions regarding the risks of MHT in this population (38), but adding estrogen 884 
seems counterintuitive when current breast cancer therapies interrupt or decrease estrogen levels. 885 
Future studies taking into account estrogen receptor status, time since diagnosis and therapy, 886 
mastectomy status, and risks for breast cancer recurrence might better inform decision-making.  887 
 888 
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Tailoring Menopausal Hormone Therapy 889 
3.1h We suggest a shared decision-making approach to decide about the choice of formulation; 890 
starting dose; the route of administration of MHT; and how to tailor MHT to each woman’s 891 
individual situation, risks, and treatment goals. (Ungraded best practice statement) 892 
Clinicians prescribe estrogen alone for women without a uterus. Starting dosages are generally 893 
lower than those in the WHI (Table 5) and the overarching principle is to use the lowest effective 894 
dose with upward titration based on clinical response. Clinicians usually do not measure estradiol 895 
levels to monitor therapy except when symptoms do not improve with escalating doses, 896 
particularly after changing the mode of administration from oral to transdermal. For younger 897 
women with surgical menopause or those with POI who are accustomed to higher baseline 898 
endogenous estradiol levels, clinicians often prescribe higher starting doses of ET (e.g., 899 
transdermal estradiol, 100 mcg), and then slowly lower the dose as tolerated. When women with 900 
premature menopause approach the age of natural menopause, the reassessment and tapering of 901 
MHT dose seems reasonable. 902 
 903 
Estrogen Preparations 904 
Oral Estrogens. Estradiol tablets or conjugated estrogens (synthetic or equine) are convenient, 905 
studied most extensively, and alleviate climacteric symptoms in a dose-dependent fashion. CEE, 906 
derived from pregnant mares’ urine and used for decades, contain more than 200 compounds 907 
with varying estrogenic potency (160). Oral micronized estradiol and other oral estrogen 908 
preparations may result in up to 5-fold higher levels of circulating estrone and 10- to 20-fold 909 
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higher estrone sulfate than transdermally administered estradiol at comparable or even higher 910 
doses. The biological effects of these estrone and estrone-sulfate increments are unknown (161-911 
163).  912 
 913 
Cutaneous and Transdermal Estradiol. Cutaneous and transdermal estradiol, administered via 914 
percutaneous gels, sprays, emulsions, or transdermal patches, have a similar efficacy as oral ET 915 
in reducing climacteric symptoms and are easily tailored to the individual (164,165). The 916 
primary advantage of transdermal ET is to alleviate the first-pass hepatic metabolic effect (166) 917 
of oral estrogens resulting in a procoagulant effect and increases in sex hormone–binding 918 
globulin, thyroid-binding globulin, cortisol-binding globulin (167,168), triglycerides, and 919 
markers of inflammation such as C-reactive protein (167,169).  920 
Transdermal therapies, at low doses, are preferable for women with a VTE risk, as evidenced by 921 
a recent meta-analysis commissioned for these guidelines (4), and they may also be preferable in 922 
patients with hypertension, hypertriglyceridemia, obesity, MetS, diabetes, or a history of 923 
gallbladder disease. Clinicians should keep in mind that there are no existing head-to-head RCTs 924 
with clinical outcomes that compare transdermal with oral therapies.  925 
 926 
Vaginal Delivery of Systemic Estrogens. Estradiol acetate vaginal rings, delivering 50 or 100 927 
mcg of estradiol daily (Table 5), provide consistent systemic estradiol levels for 3-months per 928 
ring insertion. They are indicated for treatment of moderate to severe VMS and VVA due to 929 
menopause (170,171). High-dose vaginal creams containing estradiol or CEE (i.e., 1-2 g) also 930 
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result in systemic estrogen levels. Concomitant progestogen is needed with these preparations to 931 
abrogate endometrial stimulation. We discuss low-dose vaginal ETs for the specific treatment of 932 
genitourinary syndrome of menopause (GSM) in Section 5.0. 933 
 934 
Progestogen Administration 935 
In women with a uterus, a progestogen must be added to prevent endometrial hyperplasia and 936 
cancer. The various formulations (Table 5) are administered in two regimens. The combined 937 
sequential regimen includes estrogen for 20 to 25 days and a progestogen for 12 to 15 days each 938 
month. This approach is preferred for recently menopausal woman who are prone to 939 
breakthrough bleeding during the first year or two of therapy. The combined continuous regimen 940 
utilizes both an estrogen and progestogen daily on a continuous basis. Clinicians can administer 941 
progestogen orally, transdermally by patch, vaginally, or by intrauterine administration (172). 942 
The levonorgestrel intrauterine device minimizes systemic progestogen absorption, but increased 943 
blood levels do occur and one observational study reported higher breast cancer incidence (173). 944 
  945 
Progestogen Alone. For those who do not tolerate ET, progestogens can relieve VMS. In RCTs, 946 
oral synthetic progestogens (Table 5) (174,175) and micronized progesterone (176) were 947 
effective. Clinical outcome trials are lacking in women with breast cancer; thus, progestogen 948 
therapy is best avoided except under limited circumstances in these patients, as the effect on 949 
recurrence is unclear (80).  950 
 951 
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Custom-compounded Hormones 952 
3.1i We recommend using MHT preparations approved by the FDA and comparable regulating 953 
bodies outside the U.S., and recommend against the use of custom-compounded hormones. 954 
(Ungraded best practice statement) 955 
 956 
Evidence 957 
A number of FDA-approved hormonal therapies are “biochemically identical” to endogenous 958 
estradiol and progesterone and are preferred to custom-compounded options. Custom-959 
compounded hormone therapies have become increasingly popular, but are not recommended 960 
because the manufacturing process lacks FDA oversight (177). Clinical trials documenting the 961 
efficacy and safety of compounded progesterone for endometrial protection are lacking. 962 
Proponents of custom-compounded hormone therapies often advise measuring salivary hormone 963 
levels to monitor therapy. However, scientific evidence is lacking to justify salivary 964 
measurements due to inter- and intra-assay variability, variable salivary flow rates dependent 965 
upon hydration, food intake, and other factors, and the inability to predict the pharmacokinetics 966 
of a custom-compounded hormone dose in a manner that would allow for valid salivary 967 
sampling.  968 
 969 
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Conjugated Equine Estrogens with Bazedoxifene  970 
3.2 For symptomatic postmenopausal women with a uterus and without contraindications, we 971 
suggest the combination of CEE/ BZA (where available) as an option for relief of VMS and 972 
prevention of bone loss. (2|⊕⊕⊕O)  973 
 974 
Evidence 975 
The combination of CEE with the SERM/BZA (available in the U.S. and licensed in the 976 
European Union) relieves VMS and vaginal atrophy and reduces bone resorption in women with 977 
a uterus; it provides an alternative to progestogen therapy for women averse to vaginal bleeding, 978 
breast tenderness, or altered mood. A series of RCTs up to 2 years’ duration evaluated effects of 979 
CEE/BZA (0.45 mg/20 mg, the approved dose) compared with MHT (CEE 0.45 mg/ MPA 1.5 980 
mg) (178-180).  981 
 982 
Benefits  983 
Vasomotor Symptoms. The number and severity of moderate-to-severe VMS were significantly 984 
decreased at 12 weeks; hot flash frequency was reduced by 74% compared with 51% for 985 
placebo, and hot flash severity was reduced up to 54%. Hot flash reduction was sustained at 12 986 
months (P < 0.05) (181).  987 
 988 
Bone Loss. Bone loss at the lumbar spine and hip was prevented in postmenopausal women at 989 
risk for osteoporosis (182), as reflected by reduction of serum bone turnover markers and 990 
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enhancement of bone mineral density versus placebo (180,181). At 12 months, CEE/BZA was 991 
less effective at the lumbar spine than CEE/MPA (180). Fracture data are lacking.  992 
Vaginal Effects. Treating postmenopausal women ages 40 to 65 with VVA at baseline (183) 993 
improved vaginal maturation at 12 weeks (181). Women reported a lower incidence of 994 
dyspareunia.  995 
 996 
Quality of Life. Secondary endpoints included improvements in sleep, health-related QOL, and 997 
improved treatment satisfaction (184,185). In RCTs, both CEE/BZA and CEE/MPA improved 998 
sleep disturbance and time to fall asleep (185).  999 
 1000 
Safety Considerations   1001 
Breast. The incidence of breast pain and tenderness was similar for CEE/BZA and placebo (185-1002 
187) and less than with CEE/MPA. After 1 year of therapy with CEE/BZA, mammographic 1003 
breast density was not appreciably different than with placebo, whereas it increased with 1004 
CEE/MPA (184). In trials up to 2 years, the rates of breast cancer (reported as adverse events, 1005 
not clinical outcomes) were not sufficient to assess risk or benefit (186,187).   1006 
 1007 
Endometrium. Cumulative amenorrhea rates for CEE /BZA were comparable with placebo and 1008 
greater than for CEE/MPA (188). At 2 years, the incidence of neither endometrial hyperplasia 1009 
nor endometrial cancer was increased (180,189).  1010 
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 1011 
Potential Risks  1012 
Adverse Events. While an osteoporosis trial found a 2-fold risk of VTE with BZA 20-mg therapy 1013 
alone (190), there was no additive effect on VTE when BZA was combined with CEE, although 1014 
adequately powered studies are necessary (181). In trials up to 2 years in women ages 40 to 65, 1015 
rates of cardiovascular events, cancers (breast, endometrial, ovarian), and mortality were similar 1016 
to placebo (191), but studies were underpowered to draw firm conclusions regarding these 1017 
endpoints.  1018 
 1019 
3.3 Tibolone  1020 
3.3a For women with bothersome VMS and climacteric symptoms and without 1021 
contraindications, we suggest tibolone (in countries where available) as an alternative to MHT. 1022 
(2|⊕⊕OO) 1023 
3.3b We recommend against adding tibolone to other forms of MHT. (1|⊕⊕OO) 1024 
3.3c We recommend against using tibolone in women with a history of breast cancer. (1|⊕⊕OO) 1025 
 1026 
Evidence 1027 
Tibolone belongs to the group of normethyltestosterone progestogen derivatives, and has 1028 
metabolites that exhibit estrogenic, progestogenic, and androgenic effects (192). This agent (193) 1029 
is available in many countries outside of the U.S. at doses of 1.25-2.5 mg/d.  1030 
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 1031 
Benefits  1032 
Menopausal Symptoms. Tibolone alleviates VMS with equivalent or lesser potency than 1033 
conventional MHT. Tibolone also improves sleep, mood, urogenital atrophy, and may improve 1034 
libido (194-197). 1035 
 1036 
Bone Loss and Fracture. Tibolone prevents postmenopausal bone loss and osteoporotic fractures 1037 
in women with osteoporosis (198,199), but is not approved for this purpose because of the 1038 
increased risk of stroke in older women with osteoporosis initiating therapy at age > 60 (199).  1039 
 1040 
Possible Risks   1041 
Endometrium. There is no endometrial thickening (197) or increase in myoma with tibolone 1042 
(200). A Cochrane analysis concluded that there was no clear evidence of endometrial cancer 1043 
with tibolone therapy (7 RCTs, n = 8,152; OR: 1.98; 95% CI, 0.73 to 5.32) (194).  1044 
 1045 
Thrombosis and CVD. In an observational study (110), tibolone did not increase the risk of 1046 
thrombosis. In an RCT of older women with osteoporosis, tibolone increased stroke (199). 1047 
 1048 
Breast and Colon Cancers. The incidence of breast tenderness is low (around 3%), (201,202), 1049 
and neither mammographic density nor invasive breast cancer was increased; however, the risk 1050 
of colon cancer was decreased (199,201). An RCT of women with a history of breast cancer, 1051 
 Confidential.  JCEM Submission 4 REVISED                     May 7, 2015; July 17 2015; August 11, 2015;  
                                                                      August 19, 2015                                                                                                                        
 
53 
 
after a median follow-up of 3.1 years, reported a higher rate of breast cancer recurrence with 1052 
tibolone (HR: 1·40; 95% CI, 1·14–1·70) (203). The study reported the greatest increase for 1053 
women taking an aromatase inhibitor (HR: 2.42; 95% CI, 1.01-5.79).  1054 
 1055 
3.4 Clinical Management of Patients Taking Hormone Therapies 1056 
Monitoring During Therapy 1057 
3.4a For women with persistent unscheduled bleeding while taking MHT, we recommend 1058 
evaluation to rule out pelvic pathology, most importantly, endometrial hyperplasia and cancer. 1059 
(1|⊕⊕⊕O) 1060 
3.4b We recommend informing women about the possible increased risk of breast cancer during 1061 
and after discontinuing EPT and emphasizing the importance of adhering to age-appropriate 1062 
breast cancer screening. (1|⊕⊕⊕O) 1063 
 1064 
Technical Remarks   1065 
Regular clinical follow-up, initially, within 1 to 3 months after starting MHT, and then every 6 to 1066 
12 months, depending upon the individual (and health care system), allows for monitoring 1067 
efficacy and side effects (abdominal/pelvic pain, mastalgia, metrorrhagia, weight gain, mood 1068 
changes, blood pressure), and if necessary, making treatment adjustments (Table 7). 1069 
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 1070 
Duration of Therapy 1071 
3.4c We suggest that the decision to continue MHT be revisited at least annually, targeting the 1072 
shortest total duration of MHT consistent with the treatment goals and evolving risk assessment 1073 
of the individual woman. (Ungraded best practice statement)  1074 
 1075 
Technical Remarks 1076 
Most published recommendations suggest using MHT for the shortest duration possible, but 1077 
strong evidence is lacking to support this recommendation. Current proposed limits on duration 1078 
of therapy are informed by large intervention trials (5 to 7 years) with extended follow-up for 13 1079 
years (44). Regarding duration of use, these data suggest that risk rates for breast cancer and 1080 
CVD increase with age and time since menopause, although the risks with ET appear to be less 1081 
than with EPT. Ovarian cancer risk may also increase relative to duration of MHT (95). We 1082 
conclude, and guidelines from other societies concur, that clinicians and patients should reassess 1083 
MHT continuation yearly, and discuss the risks (and individual benefits) beyond 5 years (55,56). 1084 
Patients likely to consider continuing therapy include those who fail an attempt to stop EPT, are 1085 
at high risk for fracture, or for whom alternative therapies are not appropriate. 1086 
3.4d For young women with POI, premature, or early menopause, without contraindications, we 1087 
suggest taking MHT until the time of anticipated natural menopause, when the advisability of 1088 
continuing MHT can be reassessed. (2|⊕⊕OO) 1089 
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 1090 
Stopping Considerations  1091 
3.4e For women preparing to discontinue MHT, we suggest a shared decision-making approach 1092 
to elicit individual preference about adopting a gradual taper versus abrupt discontinuation. 1093 
(2|⊕⊕OO) 1094 
 1095 
Evidence  1096 
A number of studies have compared methods (i.e., taper protocols vs. abrupt cessation) to 1097 
facilitate the discontinuation of MHT (204-207), and have detected no differences. Therefore, the 1098 
approach to discontinuation is an individual choice. Anecdotally, some women find that a very 1099 
low dose of ET maintains adequate symptom  relief and well-being, and prefer that to complete 1100 
discontinuation. 1101 
Menopausal symptoms and joint pain can recur when MHT is discontinued (44). Depending on 1102 
the severity of the symptoms, women may elect to restart MHT, perhaps at a lower dose or seek 1103 
relief with non-hormonal therapies. Accelerated bone loss was reported following the 1104 
discontinuation of MHT, whereas in contrast, bone density is stable for some years after 1105 
discontinuing bisphosphonate therapy. Bisphosphonates, however, remain in bone indefinitely, 1106 
and most expert groups do not recommend initiating bisphosphonate therapy for osteoporosis 1107 
prevention in women aged 50 to 59. Adverse effects such as osteonecrosis of the jaw and 1108 
atypical femur fractures, while rare, increase with the duration of therapy. Furthermore, as 1109 
opposed to reports from observational studies (208), in the long-term follow up of the WHI, hip 1110 
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fracture rates did not increase during 5 to 7 years of observation after MHT was discontinued 1111 
(44). Breast cancer risk following 5 years of EPT in the WHI persisted 7 years after 1112 
discontinuation. A large meta-analysis of observational studies found a persistent risk of ovarian 1113 
cancer up to a decade after discontinuing MHT (95). Urinary incontinence persisted after oral 1114 
MHT was discontinued; however, the percentage of affected women was approximately one 1115 
third less than during active treatment (44). MHT discontinuation may result in symptoms of 1116 
VVA (Section 5.0), and when oral therapy is discontinued, glucose, cholesterol, triglycerides, 1117 
calcium, and TSH levels may change (209). 1118 
 1119 
4.0 Non-hormonal Therapies for VMS  1120 
4.0 For postmenopausal women with mild or less bothersome hot flashes, we suggest a series of 1121 
steps that do not involve medication, such as turning down the thermostat, dressing in layers, 1122 
avoiding alcohol and spicy foods, and reducing obesity and stress. (2|⊕⊕OO) 1123 
 1124 
Evidence 1125 
As hot flashes result from alterations of the thermoregulatory neutral zone, shedding layers of 1126 
clothing, using fans, keeping the bedroom cool (30), avoiding alcohol and spicy foods, and 1127 
reducing stress may be effective. Being overweight or obese is a risk factor for VMS 1128 
(26,210,211) and weight loss may reduce hot flash frequency (212-214).  1129 
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 1130 
4.1 Non-hormonal Prescription Therapies for VMS 1131 
4.1a For women seeking pharmacological management for moderate to severe VMS for whom 1132 
MHT is contraindicated, or who choose not to take MHT, we recommend SSRIs /SNRIs or 1133 
gabapentin or pregabalin (if there are no contraindications). (1|⊕⊕⊕O) 1134 
 1135 
Evidence 1136 
The interpretation of hot flash efficacy studies requires an appreciation of an important 1137 
confounding factor. There is a strong, consistently-reported placebo effect, which averages 30% 1138 
(range 4-57%; Figure 4) and occurs more often in women with high anxiety and stress scores 1139 
(215-220). Clinical trials of paroxetine, venlafaxine, desvenlafaxine, citalopram, and 1140 
escitalopram demonstrate statistically significant efficacy with a reduction of frequency of hot 1141 
flashes ranging from 25 to 69% (Figure 4). The composite score of hot flash frequency and 1142 
severity is reduced by 27-61%. Other agents such as sertraline and fluoxetine are associated with 1143 
non–statistically significant trends toward the reduction of hot flashes and inconsistent results 1144 
(221-223). 1145 
Meta-analyses and a Cochrane review concluded that SSRIs and SNRIs exert mild-to-moderate 1146 
effects to reduce hot flashes in women with a history of breast cancer (217,224-227). Each of 1147 
these agents appears to have similar efficacy in breast cancer survivors as in healthy menopausal 1148 
women, although studies are small (217,228-234). Caution is advised in the use of paroxetine in 1149 
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patients taking tamoxifen, as paroxetine markedly interferes with the metabolism of tamoxifen to 1150 
its metabolite, endoxifen (221,222,224,235-237).   1151 
The only FDA-approved agent in this class is low-dose paroxetine mesylate, but others have 1152 
been used off-label in the U.S. No direct trials are available to determine the relative efficacy of 1153 
one over another. We describe suggested daily doses, efficacy, side effects, and contraindications 1154 
in Figure 4. In general, the evidence suggests that these agents are effective and well tolerated. 1155 
  1156 
Gabapentin 1157 
Four RCTs confirmed moderate efficacy in relieving hot flashes (238-241). On the basis of 1158 
clinical experience, women whose hot flashes occur primarily at night respond well to a single 1159 
bedtime dose. Individual dose requirements vary widely, as determined by empiric dose 1160 
escalation, and range from 300 to 1200 mg. Gabapentin effects as a sedative and a reducer of 1161 
vasomotor instability work well together when used at bedtime, as sedating side effects dissipate 1162 
by morning. However, when used during the day, gabapentin may result in a level of lethargy 1163 
that is not tolerable.  1164 
 1165 
Pregabalin 1166 
In one 6-week RCT, pregabalin, 75-150 mg twice daily, decreased mean hot flash scores by 65 1167 
and 71% compared with 50% by placebo (242) and was reasonably well tolerated.  1168 
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Choice of SSRI/SNRI versus Gabapentin/Pregabalin  1169 
A randomized, crossover, multicenter trial that compared recommended doses of venlafaxine 1170 
versus gabapentin, 300 mg, 3 times a day, (243) reported that both agents reduced hot flash 1171 
scores by 66%, but two-thirds of patients preferred venlafaxine over gabapentin. The quality of 1172 
this comparative evidence is low due to imprecision. 1173 
 1174 
Relative Efficacy of Nonhormonal Prescription Therapies versus Estrogens 1175 
A limited number of head-to-head RCTs have compared varying estrogen doses, preparations, 1176 
and routes of administration with nonhormonal agents (213,240,244). None of the RCTs 1177 
established statistically significant superiority of one treatment regimen over another. However, 1178 
when these and other published data are taken into account (128,213,217,236,245), the limited 1179 
evidence available suggests that standard-dose MHT is more effective than nonhormonal agents.  1180 
4.1b For those women seeking relief of moderate to severe VMS who are not responding to or 1181 
tolerating the non-hormonal prescription therapies SSRIs/SNRIs or gabapentin or pregabalin, we 1182 
suggest a trial of clonidine (if there are no contraindications). (2|⊕⊕OO) 1183 
 1184 
Evidence 1185 
Clonidine 1186 
Several RCTs demonstrated that this alpha-2-adrenergic receptor agonist reduced hot flashes but 1187 
less effectively than the SSRI/SNRIs, gabapentin, and pregabalin, and with more side effects 1188 
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(Figure 4) (217,236). Clonidine transdermal patches are preferred over tablets because of more 1189 
stable blood levels. 1190 
 1191 
4.2 Over-the-Counter and Alternative Nonhormonal Therapies for Vasomotor Symptoms  1192 
4.2 For women seeking relief of VMS with over-the-counter (OTC) or complementary medicine 1193 
therapies, we suggest counseling regarding the lack of consistent evidence for benefit for 1194 
botanicals, black cohosh, omega-3 fatty acids, red clover, vitamin E, and mind/body alternatives 1195 
including anxiety control, acupuncture, paced breathing, and hypnosis. (2|⊕⊕OO) 1196 
 1197 
Evidence 1198 
Clinical trials with these agents have reported inconsistent efficacy over placebo but individual 1199 
patients may experience benefit (Table 8). The MSFLASH trial showed that omega-3 fatty acids 1200 
do not improve VMS (246). In an randomized trial of 187 symptomatic menopausal women, 1201 
clinical hypnosis was associated with a 74.2% reduction in hot flashes compared with a 17.1% 1202 
reduction in women randomized to structured attention control (P < 0.001) (247). The 1203 
phytoestrogens are nonsteroidal compounds that have both estrogenic and antiestrogenic 1204 
properties. Caution is advised, as some of these agents, when consumed as supplements, can 1205 
exert estrogenic effects, a concern in breast cancer survivors; although dietary soy appears to 1206 
have no adverse effects on breast cancer prognosis (248).  1207 
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 1208 
5.0 Treatment of Genitourinary Syndrome of Menopause   1209 
5.1 Vaginal Moisturizers and Lubricants 1210 
5.1a For postmenopausal women with symptoms of VVA, we suggest a trial of vaginal 1211 
moisturizers to be used at least twice weekly. (2|⊕⊕OO)  1212 
 1213 
Evidence  1214 
Vaginal moisturizers (e.g., polycarbophil-based moisturizer, hyaluronic acid-based preparations, 1215 
and a pectin-based preparation), when used regularly (at least twice weekly), may provide an 1216 
effective nonhormonal approach to alleviating symptoms of vaginal atrophy. However, studies 1217 
have been small, mostly open-labeled, and limited to 12 weeks (249-257). While helpful, these 1218 
approaches are not likely as effective as vaginal ET. Vaginal moisturizers have not been shown 1219 
to reduce urinary tract symptoms or asymptomatic bacteriuria. Use of a vaginal moisturizer may 1220 
not eliminate the need for a vaginal lubricant during intercourse. 1221 
 1222 
5.1b For women who do not produce sufficient vaginal secretions for comfortable sexual 1223 
activity, we suggest vaginal lubricants. (2|⊕⊕OO) 1224 
 1225 
Evidence  1226 
Vaginal lubricants are used to enhance the sexual experience in women with symptoms of VVA 1227 
by alleviating vaginal dryness and preventing dyspareunia (258). Lubricants do not treat the 1228 
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underlying problem and only briefly alleviate symptoms. Several OTC options are available. 1229 
Since data do not demonstrate the superiority of one to another, women can experiment with 1230 
these products. Olive oil is also effective (259). Petroleum jelly has been associated with an 1231 
increased rate of bacterial vaginosis (260). 1232 
 1233 
5.2 Vaginal Estrogen Therapies 1234 
5.2a For women without a history of hormone- (estrogen) dependent cancers who are seeking 1235 
relief from symptoms of genitourinary syndrome of menopause (GSM) (including VVA) that 1236 
persist despite using vaginal lubricants and moisturizers, we recommend low-dose vaginal 1237 
estrogen therapy. (1|⊕⊕⊕O)  1238 
 1239 
Evidence 1240 
A 2006 Cochrane meta-analysis of vaginal estrogens (261) compared 19 efficacy trials and found 1241 
that all products effectively alleviated symptoms, but study differences limited comparisons 1242 
among agents. As a guiding principle, we recommend using the lowest effective dose.  1243 
RCTs of low-dose vaginal estrogen products (262-267) report rapid improvement of vaginal 1244 
symptoms (vaginal dryness or dyspareunia) and urinary symptoms (dysuria and urge 1245 
incontinence) within 2 to 3 weeks. Objective improvements continue at 12 weeks and are 1246 
maintained to 1 year. Limited evidence suggests that vaginal ET may prevent recurrent urinary 1247 
tract infections (268,269) and overactive bladder (270,271). No clear proof exists that vaginal ET 1248 
prevents or improves pelvic prolapse (272) but may be advantageous preoperatively (273). 1249 
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Adverse effects include potential transfer to partner via penile or oral absorption, and with 1250 
vaginal creams, residue on undergarments. 1251 
 1252 
Vaginal Estrogens 1253 
Vaginal estrogen preparations have been categorized as (1) low, (2) intermediate, and (3) 1254 
systemic doses (274) (Table 9). By using the lowest effective doses, systemic absorption is 1255 
minimized. During the initiation of therapy, vaginal atrophy may enhance systemic absorption, 1256 
although not all studies demonstrate this effect (267,275). When vaginal epithelium is restored 1257 
(after several weeks of ET), systemic absorption may decrease (276,277). 1258 
 1259 
Low-Dose Therapies 1260 
Low-Dose Vaginal Ring. Low-dose vaginal rings result in estradiol levels that remain within the 1261 
normal postmenopausal range; however, bone resorption and lipid levels decrease, suggesting 1262 
possible systemic effects (278,279). Insertion and removal at 3-month intervals may be difficult, 1263 
the ring can be sensed during intercourse, and it can be expelled, particularly in women who 1264 
have undergone a hysterectomy (265).  1265 
 1266 
Vaginal Estradiol Tablets. The 10-mcg tablet provides standard twice weekly dosing, relieves 1267 
vaginal symptoms by 8 weeks, and is effective for at least 52 weeks (263,275,280,281). Therapy 1268 
is initiated with daily administration for 2 weeks and then twice weekly thereafter. Vaginal 1269 
placement of the tablet may provide less introital benefit than creams.  1270 
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 1271 
Promestriene (Estradiol Diether). This is a low-dose estrogen used outside the U.S. Evidence is 1272 
limited to studies of poor quality, and very few RCTs (282). 1273 
 1274 
Intermediate-Dose Vaginal Estrogen  1275 
The 25 mcg estradiol tablets increase plasma estradiol from 3.1±0.83 to 19.8±6.1 pg/ml by 7 1276 
days (283). An RCT of CEE vaginal cream > 0.3 mg applied daily or twice weekly reported an 1277 
improvement in VVA by 12 weeks that was sustained for 52 weeks without reports of 1278 
endometrial effects (266). Intermediate-dose estradiol and CEE creams provide flexibility of 1279 
dosing, allow treatment from the introitus to the vaginal apex, and provide the emollient effect of 1280 
vehicle. Some systemic absorption exists (284,285).  1281 
 1282 
Systemic-Dose Vaginal Estrogen  1283 
CEE 0.625 mg to 2.5 mg vaginal cream, administered daily, results in systemic effects as 1284 
evidenced by LH and FSH suppression (285). No RCT data are available regarding the FDA-1285 
approved dosing of estradiol 2- to 4-g vaginal cream, administered daily for 1 to 2 weeks, 1286 
followed by a maintenance dosage of 1 g, 1 to 3 times a week.  1287 
 1288 
Other Hormonal Agents 1289 
 Estriol vaginal preparations (gels and suppositories} are manufactured and government 1290 
regulated in a number of countries outside the U.S. Estriol is considered a low affinity estrogen, 1291 
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and despite increased plasma concentration after repeated vaginal administration, is not 1292 
considered to have substantial systemic effects (286,287). 1293 
 1294 
Adverse Events   1295 
As serum estradiol levels during therapy usually fall within the normal postmenopausal range, 1296 
the risk profile with low-dose vaginal ET is expected to be lower than with systemic ET (288). 1297 
However, long-term endometrial safety data are lacking, and 1 year is the maximum duration of 1298 
RCTs of vaginal ET (261). Side effects include vulvovaginal candidiasis (289,290), and, with 1299 
higher dosing and systemic absorption, vaginal bleeding and breast pain (289). Increased CVD 1300 
or VTE risk has not been reported (261). This may reflect an actual neutral effect due to the 1301 
absence of a first-pass hepatic effect by vaginal estrogens, or that studies of women at high CVD 1302 
or VTE risk are lacking (281). Available evidence does not support the boxed warning on low-1303 
dose vaginal estrogen regarding an increased risk of CHD, stroke, VTE, dementia, and breast 1304 
cancer, and efforts to modify the labeling of these products are in progress (288). 1305 
 1306 
Practice Statement  1307 
 5.2b In women with a history of breast or endometrial cancer, who present with symptomatic 1308 
GSM (including VVA), that does not respond to non-hormonal therapies, we suggest a shared 1309 
decision-making approach that includes the treating oncologist to discuss using low-dose vaginal 1310 
ET. (Ungraded best practice statement) 1311 
 1312 
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Evidence 1313 
Breast Cancer 1314 
Whether small increases in circulating estrogens from low-dose vaginal estrogen can stimulate 1315 
the growth of residual breast cancer cells (280,291-293) remains an unanswered question. 1316 
However, for women taking aromatase inhibitors, the effectiveness of which depends upon 1317 
blocking up to 95% of estrogen synthesis and reducing circulating estradiol levels to <1 pg/ml 1318 
(250), caution is raised, because minimal amounts of estrogen can be absorbed with low-dose 1319 
vaginal ET. In a cohort case-control study of 13,479 breast cancer survivors taking adjuvant 1320 
tamoxifen or aromatase inhibitor therapy for at least 1 year, after 3.5 years of concurrent 1321 
administration of the low-dose estrogen ring or 10-mcg vaginal tablet, breast cancer recurrence 1322 
did not increase (RR: 0.78; 95% CI, 0.48-1.25) (294). These data are insufficient, however, to 1323 
conclude safety and to recommend this approach.  1324 
 1325 
Endometrial Cancer 1326 
The effect of low-dose vaginal ET on endometrial cancer recurrence is unknown. The only RCT 1327 
attempting to evaluate the effect of systemic ET on recurrence rate and survival in women after 1328 
surgery for stage I or II endometrial cancer was closed prematurely without complete enrollment 1329 
(295). In the absence of RCT findings to guide practice recommendations, the decision to use ET 1330 
remains controversial and involves assessing the severity of postmenopausal symptoms and 1331 
tumor characteristics (296,297). 1332 
 1333 
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5.2c For women taking raloxifene, without a history of hormone- (estrogen) dependent cancers, 1334 
who develop symptoms of GSM (including VVA) that do not respond to non-hormonal 1335 
therapies, we suggest adding low-dose vaginal ET. (2|⊕⊕OO) 1336 
 1337 
Evidence 1338 
Raloxifene has neutral vaginal effects (298-300). In two clinical trials, vaginal, but not oral (301) 1339 
ET, was safely used to treat vaginal symptoms in women taking raloxifene without untoward 1340 
endometrial effects (302,303).  1341 
 1342 
5.2d For women using low-dose vaginal estrogen therapy, we suggest against adding a 1343 
progestogen (i.e., no need for adding progestogen to prevent endometrial hyperplasia). 1344 
(2|⊕OOO) 1345 
5.2e For women using vaginal estrogen therapy who report postmenopausal bleeding or spotting, 1346 
we recommend prompt evaluation for endometrial pathology. (1|⊕⊕OO) 1347 
 1348 
Evidence 1349 
Bleeding or spotting in a woman using only vaginal estrogens is uncommon in the absence of 1350 
endometrial pathology. The 2006 Cochrane review of 19 studies (261) found no significant 1351 
difference among vaginal creams, tablets, or rings in terms of endometrial thickness or 1352 
hyperplasia or in the proportion of women with adverse events (261). Recent 1-year-long studies 1353 
of vaginal CEE cream and low-dose vaginal estradiol tablets revealed no cases of endometrial 1354 
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hyperplasia or cancer as determined by endometrial biopsy (263,266,304). Vaginal 1355 
administration of estradiol tablets, when placed in the upper third of the vagina, may result in a 1356 
uterine first-pass effect resulting in a higher degree of uterine stimulation (305-309). It is 1357 
unknown if endometrial proliferation, hyperplasia, or cancer can occur after long-duration 1358 
treatment (> 1 year) or in women with risk factors (late menopause, higher body mass index, 1359 
higher dosing). For women at higher risk of endometrial cancer, surveillance using transvaginal 1360 
ultrasound, followed by endometrial biopsy if endometrial thickening is present, may be prudent. 1361 
Intermittent (possibly annual) progestogen withdrawal may be considered to assess endometrial 1362 
status (261,280).  1363 
 1364 
5.3 Ospemifene 1365 
5.3a For treatment of moderate to severe dyspareunia associated with vaginal atrophy in 1366 
postmenopausal women without contraindications, we suggest a trial of ospemifene. (2|⊕⊕⊕O) 1367 
5.3b For women with a history of breast cancer presenting with dyspareunia, we recommend 1368 
against ospemifene. (1|⊕OOO) 1369 
 1370 
Evidence 1371 
Benefits 1372 
Not all women are comfortable using vaginal ET and may prefer an oral medication specifically 1373 
indicated for dyspareunia.  1374 
 1375 
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Vaginal Symptoms and Sexual Function. Two 12-week RCTs of ospemifene reported 1376 
improvements in pH and vaginal maturation index, severity of dyspareunia (310,311), and 1377 
standardized measures of sexual function (including desire, arousal, orgasm, and satisfaction) 1378 
(312). Two year-long studies (313,314) demonstrated sustained vaginal benefits.  1379 
 1380 
Risks 1381 
Vasomotor symptoms. The most common adverse effect was VMS (7.2% of women taking 1382 
ospemifene compared with 2% taking placebo) (314).  1383 
 1384 
Cardiovascular. Ospemifene involves risk of VTE (315) and is contraindicated in women at risk 1385 
for venous or arterial thrombosis or stroke. In safety studies, incidence rates for thromboembolic 1386 
stroke, hemorrhagic stroke, and DVT were 0.72, 1.45, and 1.45/1,000 respectively in women 1387 
receiving ospemifene 60 mg versus 1.04, 0, and 1.04/1,000, respectively in women assigned to 1388 
placebo (310).  1389 
 1390 
Endometrium. No cases of endometrial carcinoma have been reported. Studies reported 1391 
endometrial thickening of > 5 mm at a rate of 60.1/1,000 women/year of therapy with 1392 
ospemifene versus 21.2/1,000 women/year of therapy with placebo. The incidence of 1393 
proliferative endometrium (weakly plus active plus disordered) was 86.1/1,000 women with 1394 
ospemifene versus 13.3/1,000 with placebo (315). The incidence of uterine polyps was 5.9 1395 
cases/1,000 women with ospemifene versus 1.8/1,000 women with placebo (315). 1396 
 Confidential.  JCEM Submission 4 REVISED                     May 7, 2015; July 17 2015; August 11, 2015;  
                                                                      August 19, 2015                                                                                                                        
 
70 
 
 1397 
Breast. Data on breast density or breast cancer risk are lacking. Estrogen-dependent neoplasia is 1398 
a contraindication. 1399 
 1400 
Future Research   1401 
There are numerous gaps in our knowledge regarding menopause symptoms. Some of these 1402 
include a lack of the most basic understanding of what causes hot flashes, questions regarding 1403 
the potential link between VMS and CVD in older versus younger postmenopausal women, and 1404 
a poor understanding of the relationships between menopause and sleep and hormonal transitions 1405 
and mood, which have significant social and economic implications. Given the uncertainties 1406 
regarding the precise neuroendocrine events that cause VMS, developing specific targeted 1407 
therapies is challenging. Establishing appropriate animal models and expanding recent research 1408 
involving the neuroregulators kisspeptin, neurokinin B, and dynorphin may help develop new 1409 
effective treatments (35). 1410 
Management of the transition to menopause remains uncharted territory. The SWAN and the 1411 
Melbourne Women’s Midlife Health Project provide extensive epidemiologic, physiologic, and 1412 
descriptive data characterizing reproductive changes that occur during the transition to 1413 
menopause. However, clinical management decisions are often based on the extrapolation of 1414 
observational data collected from studies conducted in younger, reproductive age women. RCTs 1415 
of frequently prescribed therapies, such as oral contraceptives, MHT, and measures to control 1416 
mood, with clinical outcomes relevant to women of relatively advanced age are sorely needed to 1417 
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confidently advise patients regarding the safest and most effective therapies to use during this 1418 
transition.  1419 
Managing the loss of ovarian function in premenopausal women due either to surgery, the range 1420 
of disorders manifesting as POI, or the sequelae of treatment for breast cancer and other 1421 
malignancies remains challenging. This is due to a dearth of quality data assessing the long-term 1422 
risks and benefits of MHT or other options for symptom relief and prevention of chronic diseases 1423 
in these groups. Fertility issues can be managed with modern assisted reproductive technology, 1424 
but we fall short on adequately managing estrogen deficiency. Pressing questions remain 1425 
regarding optimal treatment preparation, dosing and regimens, and the merits of long-term MHT, 1426 
even in women without menopausal symptoms. International registries and clinical trials are 1427 
overdue to address the long-reaching implications of these important issues.  1428 
The most persistent question for naturally postmenopausal women is how to balance menopausal 1429 
symptom relief with the prevention of chronic diseases of aging such as CHD, osteoporotic 1430 
fractures, and dementia. ET has long been hypothesized to meet this goal, although conclusive 1431 
evidence remains elusive, and questions persist regarding the interaction between EPT and these 1432 
outcomes, as well as breast cancer. Observational data suggesting differences in VTE risk and 1433 
other CVD outcomes continue to accumulate, suggesting a significant need for adequately 1434 
powered clinical trials comparing the safety and efficacy of oral with transdermal therapies in 1435 
younger, recently postmenopausal women.  1436 
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Finally, new SERM therapies (alone and partnered with estrogens) are promising, but larger, 1437 
longer trials are needed to fully characterize the benefit/risk profiles of these new treatments and 1438 
inform the clinician as to which patients stand to benefit the most from their use.  1439 
 1440 
 1441 
 1442 
 1443 
 1444 
 1445 
 1446 
 1447 
 1448 
 1449 
 1450 
  1451 
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Table 1. Definitions of spectrum of menopause  1452 
 1453 
Menopause: Clinical status after the final menstrual period, diagnosed retrospectively after cessation of menses for 
12 months in a previously cycling woman and reflecting complete or nearly complete permanent cessation of ovarian 
function and fertility  
Spontaneous menopause: Cessation of menses that occurs at an average age of 51 in the absence of surgery or 
medication (316-318) 
Menopausal transition (or perimenopause): An interval preceding the menopause characterized by variations in 
menstrual cycle length and bleeding pattern, mood shifts, vasomotor, and vaginal symptoms and with rising FSH 
levels and falling AMH and inhibin B levels, which starts during the late reproductive stage and progresses during the 
menopause transition (15,319) 
Climacteric: The phase in the aging of women marking the transition from the reproductive phase to the non-
reproductive state. This phase incorporates the perimenopause by extending for a longer variable period before and 
after the perimenopause 
Climacteric syndrome: When the climacteric is associated with symptomatology 
Menopause following hysterectomy without oophorectomy: Spontaneous cessation of ovarian function without 
the clinical signal of cessation of menses 
Induced menopause: Cessation of ovarian function induced by chemotherapy, radiotherapy, or bilateral 
oophorectomy 
Early menopause: Cessation of ovarian function occurring between ages 40 to 45 in the absence of other etiologies 
for secondary amenorrhea (pregnancy, hyperprolactinemia, and thyroid disorders) 
POI: Loss of ovarian function before the age of 40 with waxing and waning course and potential resumption of 
menses, conception, and pregnancy (320) 
The prevalence of POI is approximately 1% (321) and differentiated into idiopathic, autoimmune (associated with 
polyglandular autoimmune syndromes), metabolic disorders, and genetic abnormalities (including fragile X 
premutation).  
POI = primary ovarian insufficiency; AMH = anti-Mullerian hormone FSH = follicle stimulating hormone 1454 
 1455 
 1456 
 1457 
 1458 
 1459 
 1460 
 1461 
 1462 
 1463 
 1464 
 1465 
 1466 
 1467 
 1468 
 1469 
 1470 
 1471 
 1472 
 1473 
 1474 
 1475 
 1476 
Table 2. Conditions that may cause or mimic vasomotor events and that can be distinguished 1477 
from menopausal symptoms by history, examination, and investigations, as indicated 1478 
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 1479 
Hormone excess 
• Thyroid hormone excess 
• Carcinoid syndrome (flushing without sweating) 
• Pheochromocytoma (hypertension, flushing, and profuse sweating) 
Dietary factors 
• Alcohol  
• Spicy food 
• Food additives (e.g., monosodium glutamate, sulfites) 
Pharmaceuticals 
• Chronic opioid use  
• Opiate withdrawal 
• SSRIs (may cause sweats)  
• Nicotinic acid (intense warmth, itching lasting up to 30 minutes) 
• Calcium channel blockers 
• Medications that block estrogen action or biosynthesis 
Chronic infection (increased body temperature) 
Other medical conditions  
• Postgastric surgery dumping syndrome  
• Mastocytosis and mast cell disorders (usually with gastrointestinal symptoms) 
• Some cancers: medullary carcinoma of the thyroid, pancreatic islet-cell tumors, renal cell carcinoma,   
lymphoma 
• Anxiety disorders 
SSRI = selective serotonin reuptake inhibitor 1480 
 1481 
 1482 
 1483 
 1484 
 1485 
 1486 
 1487 
 1488 
 1489 
 1490 
 1491 
 1492 
 1493 
 1494 
 1495 
 1496 
 1497 
 1498 
 1499 
 1500 
 1501 
Table 3. Genitourinary syndrome of menopause  1502 
 1503 
 Symptoms 
• Vulvar pain, burning, or itching 
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• Vaginal dryness 
• Vaginal discharge  
• Dyspareunia  
• Spotting or bleeding after intercourse 
• Dysuria, urinary frequency, urgency 
• Recurrent urinary tract infections 
Signs, external genitalia 
• Decreased labial size  
• Loss of vulvar fat pads 
• Vulvar fissures 
• Receded or phimotic clitoris 
• Prominent urethra with mucosal eversion or prolapse   
Signs, vagina  
• Introital narrowing 
• Loss of elasticity with constriction 
• Thin vaginal epithelial lining  
• Loss of mature squamous epithelium  
• Pale or erythematous appearance    
• Petechiae, ulcerations, or tears  
• Alkaline pH (> 5.5) 
• Infection (yellow or greenish discharge) 
 1504 
Derived from Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference P 2014 Genitourinary 1505 
syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's 1506 
Sexual Health and the North American Menopause Society. Menopause 21:1063-1068 (37) 1507 
 1508 
 1509 
 1510 
 1511 
 1512 
 1513 
 1514 
 1515 
 1516 
 1517 
 1518 
 1519 
 1520 
 1521 
 1522 
 1523 
 1524 
 1525 
Table 4. Specific cautions to use of systemic menopausal hormone therapy or selective estrogen 1526 
receptor modulators*† for treatment of menopausal symptoms     1527 
 1528 
In general, estrogen therapy, should not be used in women with any of the 
following conditions: 
• Undiagnosed abnormal genital bleeding 
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• Known, suspected, or history of cancer of the breast 
• Known or suspected estrogen-dependent neoplasia including endometrial 
cancer 
• Active deep vein thrombosis, pulmonary embolism or history of these 
conditions 
• Active arterial thromboembolic disease (for example, stroke, myocardial 
infarction), or a history of these conditions 
• Known anaphylactic reaction or angioedema in response to any ingredient 
in the medication‡ 
• Known liver impairment or disease 
• Known protein C, protein S, or antithrombin deficiency, or other known 
thrombophilic disorders‡ 
• Known or suspected pregnancy 
 
Caution should also be exercised in women with: 
• Gallbladder disease(oral ET) 
• Hypertriglyceridemia (> 400 mg/d)(oral ET) 
• Diabetes 
• Hypoparathyroidism (risk of hypocalcemia) 
• Benign meningioma 
• Intermediate or high risk of breast cancer 
• High risk of heart disease 
• Migraine with aura (oral ET) 
• Other conditions § 
 
*  Also apply to conjugated estrogens/bazedoxifene, ospemifene, and tibolone therapies 1529 
† Advice not to use estrogens in the specific conditions listed is based on Food and Drug Administration recommendations and 1530 
package labeling in the U.S. The advice to exercise caution is based on a review of the literature (including package labeling) and 1531 
not dictums generally included in various menopause society guidelines. As these guidelines are meant to be used internationally, 1532 
it should be noted that these considerations may vary from country to country.  1533 
‡ Specific to conjugated equine estrogens + combination with bazedoxifene 1534 
§Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus 1535 
erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions. 1536 
ET = estrogen therapy 1537 
 1538 
 1539 
 1540 
 1541 
 1542 
 1543 
 1544 
 1545 
Table 5. Commonly prescribed hormone therapies 1546 
 1547 
Systemic Estrogen Therapies* 
Preparation 
Oral Estrogen Tablets 
  
Doses/d 
 
Comments 
Micronized 17-B estradiol (E2)  0.5, 1.0, 2.0 mg  
Estradiol valerate† 1.5 mg  
CEE 0.3, 0.45, 0.625 mg Higher doses available 
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Preparation used in WHI 
 
Preparation 
Transdermal Estrogens 
  
Doses 
 
Comments 
Estradiol patch 0.025 to 0.1 mg once or twice 
weekly depending on 
preparation  
 
0.014 mg /wk 
Corresponds to 0.5 to 2.0 mg estradiol 
tablets  
Diffusion from one patch to another can be 
different 
Preserved bone in women > 60 y 
Estradiol percutaneous gel 0.25–1.5 mg qd  Corresponds to 0.5 to 2.0 mg estradiol 
tablets  
Can be transferred to persons and pets by 
skin contact  
Estradiol transdermal spray 1.5 mg qd  Estradiol via spray  
Can be transferred to persons and pets by 
skin contact 
 
Preparation 
Vaginal ring 
  
Doses/d 
 
Comments 
Estradiol acetate 0.05-0.10 mg Systemic levels of estradiol provides relief 
of VMS; 90-d duration/ ring 
   
Progestogen Therapies 
Preparation 
Oral Progestin Tablets 
  
Doses/d  
 
Comments 
Medroxyprogesterone acetate 2.5, 5, 10 mg Utilized in WHI 
Norethindrone 0.35 mg  
Norethindrone acetate  5.0 mg  
Megestrol acetate 20, 40 mg  
Dydrogesterone† 10 mg  
Chlormadinone acetate† 5, 10 mg  
Medrogestone† 5 mg  
Nomegestrol acetate†  3.75, 5 mg  
Promegestone† 0.125, 0.25, 0.5 mg  
 
Preparation 
Oral capsule: progesterone 
  
Doses/d  
 
Comments 
Micronized progesterone 100, 200 mg  In peanut oil; avoid if peanut allergy. May 
cause drowsiness and should be taken at 
bedtime. 
 
 1548 
 1549 
 1550 
Table 5. Commonly prescribed hormone therapies (cont.) 1551 
 1552 
Preparation 
Intrauterine system: progestin‡ 
  
Doses/d  
 
Comments 
Levonorgestrel 20 mcg released/d 
 6 mcg/d 
IUD for 5-year use 
IUD for 3-year use 
 
Preparation 
Vaginal gel: progesterone‡ 
  
Doses 
 
Comments 
Progesterone  4%, 8% 45- or 90-mg applicator 
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Combination Hormone Therapies 
Preparation 
Oral 
  
Doses/ day 
 
Comments 
CEE+MPA 0.3-0.625mg /1.5-5mg Cyclic or continuous 
E2+Neta 0.5-1mg /0.1-0.5 mg   Continuous 
E2 + drospirenone                      0.5-1mg /0.25-1 mg   Continuous 
E2 + norgestimate 1mg, 1/0.09 mg   Cycle 3 days E alone, 3 days E+P,  
E2+ Dydrogesterone † 1-2 mg /5-10 mg Cyclic and continuous 
E2 + Cyproterone acetate†        2mg /1 mg Continuous 
E2 + MPA† 1-2mg /2-10 mg 
 
Continuous 
 
CEE + bazedoxifene§                          0.45 mg /20 mg Continuous 
 
Preparation 
Transdermal 
  
Doses/patch 
 
Comments 
E2 + Neta 50µg/0.14-0.25 mg Twice weekly 
E2 + LNorg 45µg/0.015 mg Once weekly 
*Not all preparations and doses are available in all countries 1553 
† Indicates only available outside U.S. 1554 
‡Not approved in the U.S. for endometrial protection when administered with postmenopausal estrogen  1555 
§ Approved indications in the U.S. include treatment of moderate to severe VMS associated with menopause and prevention of 1556 
postmenopausal osteoporosis. In the European Union, the indications states: treatment of estrogen deficiency symptoms in 1557 
postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-1558 
containing therapy is not appropriate. The experience treating women older than 65 is limited.  1559 
CEE = conjugated equine estrogens; E = estrogen; Lnorg = levonorgestrel; Neta = norethindrone acetate or norethisterone 1560 
acetate; MPA = medroxyprogesterone acetate; qd = once daily; d = day 1561 
 1562 
 1563 
 1564 
  1565 
 Confidential.  JCEM Submission 4 REVISED                     May 7, 2015; July 17 2015; August 11, 2015;  
                                                                      August 19, 2015                                                                                                                        
 
79 
 
Table 6. Evaluating CVD and breast cancer risk in women contemplating MHT  1566 
 1567 
10-yr CVD Risk   Years since Menopause Onset 
< 5 y 6 to 10 y 
Low  
(<5%) 
MHT ok MHT ok 
Moderate 
 (5 to 10%) 
MHT ok 
(Choose Transdermal) 
MHT ok 
(Choose Transdermal) 
High** 
  (>10%) 
Avoid MHT Avoid MHT 
 1568 
Breast Cancer Risk Cutoffs for Counseling before Recommending MHT* 
Risk Category*** 5-Year NCI or IBIS Breast Cancer 
Risk Assessment 
Suggested Approach 
Low < 1.67 % MHT ok 
Intermediate 1.67- 5 % Caution† 
 
High > 5 % Avoid 
*CVD Risk calculated by ACC/AHA Cardiovascular Risk Calculator (144).  1569 
 Methods to calculate risk and risk stratification vary among countries. 1570 
**High risk includes known MI, stroke, peripheral artery disease, etc. 1571 
***Categories here newly defined for these guidelines and based on recommendations published for use of anti-estrogens for 1572 
breast cancer prevention (53,153,322,323). The assumption is that candidates for breast cancer prevention with antiestrogens 1573 
should not be candidates for initiating MHT. Method to calculate risk varies among countries. 1574 
†Caution indicates need for detailed counseling regarding anticipated benefits and risks of MHT with strong consideration of 1575 
non-hormonal therapies for symptom relief, and possible consideration of chemopreventive strategies for women who meet 1576 
suggested criteria. 1577 
CVD = cardiovascular disease:  IBIS = International Breast Intervention Study; NCI = National Cancer Institute; MHT = 1578 
menopausal hormone therapy; y = year;  1579 
Derived from Manson JE 2014 Current recommendations: what is the clinician to do? Fertility and sterility 101:916-921 (63) 1580 
 1581 
 1582 
 1583 
 1584 
 1585 
 1586 
 1587 
 1588 
 1589 
 1590 
 1591 
 1592 
 1593 
 1594 
 1595 
 1596 
 1597 
 1598 
 1599 
 1600 
 1601 
 1602 
Table 7: Clinical caveats during treatment with MHT 1603 
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 1604 
Symptom/ Condition when MHT Started Approach to Resolution 
Persistent, intolerable VMS -Switch mode of administration or adjust dose of 
estrogen and/or progestogen 
Hot flashes that persist after treatment adjustment 
 
-Consider another etiology of flashes (Table 2) 
-Ensure absorption: if transdermal, consider serum 
estradiol determination 
Bleeding 
Approach depends on:  
-Time since menopause,  
-MHT regimen,  
-Duration of therapy 
-Duration and character of bleeding 
- Sequential regimen may be more appropriate for 
recently menopausal (< 2 y), since unscheduled bleeding 
with continuous combined can be problematic 
- Persistent irregular bleeding (> 6 m) should be 
evaluated for endometrial pathology; if obese, DM, or FH 
for endometrial cancer, evaluate sooner 
-Atrophic endometrium in women more remote from 
menopause may respond to increase estrogen dose if 
otherwise appropriate  
Breast tenderness -Usually responds to a reduction in estrogen dose or 
change in progestogen preparation 
- CEE/BZA may improve symptoms   
-Changing to tibolone may be helpful in women who 
develop mastalgia on conventional MHT. 
Baseline TG level > 200 mg/dl -Review family history and seek contributing factors.  
-Transdermal estrogen therapy is preferred; 
- if oral estrogen is selected, monitor serum TG levels 2 
weeks after starting therapy 
Hypothyroid on thyroid replacement -Monitor TSH 6 to 12 wk after starting oral MHT; 
thyroxine dose may need to be increased (209).  
CEE/BZA= conjugated equine estrogens/bazedoxifene; DM = diabetes mellitus;  FH = family history; MHT = menopausal 1605 
hormone therapy; TG = triglycerides; TSH = thyroid-stimulating hormone; VMS = vasomotor symptoms; wk = week 1606 
 1607 
 1608 
 1609 
 1610 
 1611 
 1612 
 1613 
 1614 
 1615 
 1616 
 1617 
 1618 
 1619 
 1620 
 1621 
 1622 
 1623 
 1624 
 1625 
 1626 
 1627 
 1628 
 1629 
Table 8. Alternative therapies for treatment of VMS 1630 
 1631 
Agents with Inconsistent Specific Agents  Comments  References  
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Reports of Benefit  
 Genistein  Purified isoflavone 
± Estrogenically active 
Breast safety not established   
(324-336) 
 Daidzein  Purified isoflavone 
 ±Estrogenically active 
Breast safety not established  
(324-336) 
 S-equol Metabolite of daidzein (337)  
 Nonpurified isoflavones  Breast safety not established    
(338) 
 Flaxseed   (225,236,328,339-
341) 
 Red clover  Breast safety not established (225,236,328,339-
341) 
 High dose extracted or 
synthesized phytoestrogen  
 (225,236,328,339-
341) 
 Dietary soy Agreement about breast safety  (248) 
 Vitamin E 10% benefit in some studies  (217,342,343) 
Reports with 
Predominantly No 
Benefit  
   
 Black cohosh Some short-term trials report benefit, most 
report no benefit.  
Breast safety not established 
Reports of liver toxicity 
(225,344-352) 
 Omega-3-fatty acids No benefit in MSFLASH trial (246) 
 Acupuncture  Not effective when compared to “sham 
acupuncture” controls  
(353-356) 
 Exercise  Exercise with sweating may increase hot 
flashes  
(357)  
 Other complementary 
approaches  
Ginseng, dong quai, wild yam, 
progesterone creams, traditional Chinese 
herbs, reflexology, magnetic devices  
(225,332) 
Agents Requiring 
Further Study  
Stellate ganglion block  Need further RCTs to establish lack of 
complications  
(358) 
 Guided relaxation  Stress management, deep breathing, 
paced respiration, guided imagery, 
mindfulness training  
(217,225,247,359-
365) 
 Hypnosis  Recent studies suggest efficacy (247) 
 Cognitive behavior 
modification  
Recent studies suggest efficacy with 
trained practitioners 
(366,367)  
RCT = randomized controlled trial 1632 
 1633 
 1634 
 1635 
 1636 
 1637 
 1638 
Table 9. Classification of government-approved vaginal estrogens  1639 
 1640 
Category Type Dose Serum Estradiol 
Level 
Low Dose    
 <20 pg/ml 
 Silastic estradiol vaginal ring 7.5 mcg  
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 Estradiol vaginal tablet 10 mcg  
 Promestriene (estradiol diether) ovule* 10 mg  
 Estriol ovule* 0.5 mg  
 Estriol+progesterone+Lactobacillus Doderleini 
ovule* 
0.2mg+2mg+341mg  
 Promestriene cream* 3mg   
 Estriol cream* 0.015-0.03mg  
Intermediate Dose 
  
   
>20 pg/ml 
 CEE vaginal cream > 0.3-mg dose  5-50 pg/ml 
 Estradiol vaginal tablet 25 mcg† 
 
 some > 20 pg/ml 
High Dose (systemic)   35-200 pg/ml 
 
 Estradiol vaginal ring  50 and 100 mcg  
 Vaginal estradiol  > 0.5 mg  
 Vaginal CEE     > 0.5 mg‡ 
 
 
* Not approved or recommended in U.S. 1641 
† No longer available in U.S. 1642 
‡ Predominantly estrone sulfate; LH suppression reflects systemic absorption 1643 
CEE = conjugated equine estrogens 1644 
 1645 
 1646 
 1647 
 1648 
  1649 
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Figure 1. Approach to menopause guideline  1650 
   1651 
 1652 
 1653 
 1654 
 1655 
 1656 
 1657 
 1658 
 1659 
 1660 
 1661 
 1662 
 1663 
 1664 
 1665 
 1666 
 1667 
 1668 
 1669 
 1670 
 1671 
 1672 
 1673 
 1674 
MHT = menopausal hormone therapy; Rx = therapy; VMS = vasomotor symptoms 1675 
 1676 
Legend: Numbers correspond to section of text addressing selected clinical issue 1677 
 1678 
 1679 
 1680 
 1681 
 1682 
 1683 
 1684 
 1685 
 1686 
 1687 
 1688 
 1689 
 1690 
Figure 2. Approach to the patient with VMS contemplating MHT   1691 
 1692 
4.0 VMS 
Moderate or severe
MHT: Patient declines,
(+) Contraindications 
2.0
Health Considerations 
for 
All Women
3.0  VMS
Moderate or severe
MHT: Patient interest,
(-) Contraindications 
5.0
Genitourinary Symptoms
- Local therapy
- Systemic therapy
Postmenopausal woman
< 60 y of age 
or
< 10 y since menopause
or
Late perimenopausal
Definitions/ Diagnosis
1.0
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 1693 
 1694 
MI = myocardial infarction; PE = pulmonary embolism; TIA = transient ischemic attack; VTE = venous thromboembolism 1695 
 1696 
 1697 
 1698 
 1699 
 1700 
Figure 3. Updated summary of the effects of orally administered CEE alone or combined with MPA 1701 
in women ages 50-59 years during intervention phase of WHI  1702 
ACCEPTABLE
ACCEPTABLE
ASSESS PATIENT CRITERIA
-Symptomatic woman with interest in MHT
who is:
- Age < 60 y or
- < 10 y since menopause
CONSIDER CIRCUMSTANCES WHERE 
MHT SHOULD NOT BE USED (TABLE 4)
Avoid if:
- Unexplained vaginal bleeding
- Stroke, TIA, MI, PE, VTE
- Breast or endometrial cancer
- Active liver disease
Exercise caution in women with:
- Diabetes
- Hypertriglyceridemia
- Active gallbladder disease
- Increased risk of breast cancer or CVD
- Migraine with aura
EVALUATE CARDIOVASCULAR RISK
EVALUATE BREAST CANCER RISK
UTERUS PRESENT ?
 Estrogen plus 
progestogen 
 Estrogen plus 
bazedoxifene
 Tibolone (where 
available)
Estrogen alone
NOYES
CONSIDER 
OTHER 
OPTIONS
CONSIDER 
OTHER 
OPTIONS
CONSIDER 
OTHER
OPTIONS
PRESENT
HIGH
HIGH to
MODERATE  
ABSENT
CONSIDER 
OTHER
OPTONS
If age > 60 or 
>10 y since 
menopause
ACCEPTABLE
YES
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 1703 
One set of analyses examined the risks and benefits of these agents in women ages 50-59 years. This figure plots these data, 1704 
which here are expressed as excess risks and benefits/1,000 women using MHT for 5 years. As women deciding to use MHT are 1705 
more likely to continue this for a period of years rather than 1 year, this figure is constructed according to that assumption. WHI 1706 
studies were not powered for age-related subset analyses, and none of the data presented in the figure is statistically significant. 1707 
Nonetheless, this figure represents the best estimates available at the present time and are likely more reliable than similar 1708 
estimates based on observational studies as reported previously in the Endocrine Society Scientific Statement (38).  1709 
The HRs and 95% CIs for the bars in the figure are listed here with reference to the alphabetical designation shown next to the 1710 
bars. a. HR 0.60 (0.35-1.04) b. HR 1.34 (0.82-2.19) c. HR 0.82 (0.50-1.34) d. HR 1.21 (0.81-1.80) e. HR 0.99 (0.53-1.85) f. HR 1711 
1.51(0.81-2.82) g. HR 1.53 (0.63-3.75) h. HR 2.05 (0.89-4.71) i. HR 1.66 (0.76-3.67)  j. HR 3.01 (1.36-6.66) k. HR 0.71 (0.30-1712 
1.67) l. HR 0.79 (0.29-2.18) m. HR 1.00 (ns-ns)  n. HR 1.12 (0.45-2.75) o.  HR 0.62 (0.30-1.29)   p. HR 0.90 (0.72-1.11) q. HR 1713 
0.82 (0.68-1.00) r. HR 5.01 (0.59-42.9) s. HR 0.17 (0.02-1.45) t. HR 0.70 (0.46-1.09) u. HR 0.67 (0.43-1.04) v. HR 0.83 (0.67-1714 
1.04) w. HR 0.85 (0.66-1.09) 1715 
CEE = conjugated equine estrogens; MPA = medroxyprogesterone acetate; WHI = Women’s Health Initiative 1716 
Reproduced from Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, 1717 
Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin 1718 
KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH, Endocrine S. Postmenopausal hormone therapy: 1719 
an Endocrine Society scientific statement. The Journal of clinical endocrinology and metabolism 2010; 95:s1-s66(274) 1720 
1721 
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Figure 4. Hot flash frequency and composite score with nonhormonal prescription therapies for 1722 
relief of VMS  1723 
 1724 
Legend 1725 
Upper panel: effect on frequency of vasomotor symptoms; Lower panel: effect on composite score (severity times frequency; 1726 
best representation of effect); Open bars:  placebo; Colored bars: therapies; Length of bars: indicate the ranges in studies; 1727 
Horizontal bar: means: All of these agents are generally well tolerated (226). Hypersensitivity or prior adverse drug reactions to 1728 
each of these agents represent contraindications. For the SSRI/SNRIs, prior neuroleptic syndrome, serotonin syndrome, and 1729 
concurrent use of MAO inhibitors are also contraindications. SSRI /SNRIs should be used with caution in patients with bipolar 1730 
disease, uncontrolled seizures, hepatic or renal insufficiency, uncontrolled hyponatremia, concurrent use of other SSRI/SNRIs or 1731 
poorly controlled hypertension. These agents uncommonly induce suicidal thoughts within the first few months of treatment. 1732 
Preliminary evidence suggests a possible increase in risk of bone fracture. Gabapentin and pregabalin may increase suicidal 1733 
thoughts and behaviors and cause drowsiness, dizziness, and impair balance and coordination. Pregabalin may impair memory 1734 
and concentration. Clonidine is contraindicated in patients with low blood pressure and may cause lightheadedness, hypotension, 1735 
headache, and constipation; sudden cessation of treatment can be associated with significant increments in blood pressure (63). 1736 
 1737 
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